

P1 1009938

REC'D 20 MAY 2003

WIPO

P&T

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

May 14, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/370,846

FILING DATE: April 08, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/10341

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS



M. SIAS  
Certifying Officer

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

04-09-02

A/HKOV

SUBSTITUTE for Provisional Application for Patent Cover Sheet PTO/SB/16 (10-01)  
 Approved for use through 10/31/2002. OMB 0651-0032  
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

DOCKET NUMBER

21078PV

JC996 U.S. PTO  
 60/370846  
 04/08/02

## INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Craig Zhijian	Lindsley Zhao	Schwenksville, Pennsylvania Lansdale, Pennsylvania

☐ Additional inventors are being named on the separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)

INHIBITORS OF AKT ACTIVITY

## CORRESPONDENCE ADDRESS

Direct all Correspondence to:

Merck & Co., Inc.  
 Patent Department - RY60-30  
 P.O. Box 2000  
 Rahway

☒ Customer Number 000210

STATE

New Jersey

ZIP CODE

07065

COUNTRY

U.S.A.

## ENCLOSED APPLICATION PARTS (check all that apply)

<input checked="" type="checkbox"/> Specification	Number of Pages	85	<input type="checkbox"/> CD(s), Number	
<input type="checkbox"/> Drawing(s)	Number of Sheets	0	<input type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76				

## METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)

<input type="checkbox"/> A check or money order is enclosed to cover the filing fees		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 13-2755	FILING FEE AMOUNT (\$)	\$160.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are: \_\_\_\_\_

Respectfully submitted,

SIGNATURE

Date 04/08/2002

TYPED or PRINTED NAME David A. Muthard

TELEPHONE (732) 594-3903

REGISTRATION NO. 35,297  
 (if appropriate)

## EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT April 8, 2002

EXPRESS MAIL NO. EL920630597US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

MAILED BY

DATE April 8, 2002

In Duplicate

TITLE OF THE INVENTION

## INHIBITORS OF AKT ACTIVITY

BACKGROUND OF THE INVENTION

5           The present invention relates to quinoxaline containing compounds that are inhibitors of the activity of one or more of the isoforms of the serine/threonine kinase, Akt (also known as PKB). The present invention also relates to pharmaceutical compositions comprising such compounds and methods of using the instant compounds in the treatment of cancer.

10           Apoptosis (programmed cell death) plays essential roles in embryonic development and pathogenesis of various diseases, such as degenerative neuronal diseases, cardiovascular diseases and cancer. Recent work has led to the identification of various pro- and anti-apoptotic gene products that are involved in the regulation or execution of programmed cell death. Expression of anti-apoptotic genes, such  
15 as Bcl2 or Bcl-x<sub>L</sub>, inhibits apoptotic cell death induced by various stimuli. On the other hand, expression of pro-apoptotic genes, such as Bax or Bad, leads to programmed cell death (Aams et al. *Science*, 281:1322-1326 (1998)). The execution of programmed cell death is mediated by caspase-1 related proteinases, including caspase-3, caspase-7, caspase-8 and caspase-9 etc (Thornberry et al. *Science*,  
20 281:1312-1316 (1998)).

          The phosphatidylinositol 3'-OH kinase (PI3K)/Akt/PKB pathway appears important for regulating cell survival/cell death (Kulik et al. *Mol. Cell. Biol.* 17:1595-1606 (1997); Franke et al, *Cell*, 88:435-437 (1997); Kauffmann-Zeh et al. *Nature* 385:544-548 (1997) Hemmings *Science*, 275:628-630 (1997); Dudek et al.,  
25 *Science*, 275:661-665 (1997)). Survival factors, such as platelet derived growth factor (PDGF), nerve growth factor (NGF) and insulin-like growth factor-1 (IGF-1), promote cell survival under various conditions by inducing the activity of PI3K (Kulik et al. 1997, Hemmings 1997). Activated PI3K leads to the production of phosphatidylinositol (3,4,5)-triphosphate (PtdIns(3,4,5)-P3), which in turn binds to,  
30 and promotes the activation of, the serine/threonine kinase Akt, which contains a pleckstrin homology (PH)-domain (Franke et al *Cell*, 81:727-736 (1995); Hemmings *Science*, 277:534 (1997); Downward, *Curr. Opin. Cell Biol.* 10:262-267 (1998), Alessi et al., *EMBO J.* 15: 6541-6551 (1996)). Specific inhibitors of PI3K or dominant negative Akt/PKB mutants abolish survival-promoting activities of these  
35 growth factors or cytokines. It has been previously disclosed that inhibitors of PI3K

(LY294002 or wortmannin) blocked the activation of Akt/PKB by upstream kinases. In addition, introduction of constitutively active PI3K or Akt/PKB mutants promotes cell survival under conditions in which cells normally undergo apoptotic cell death (Kulik et al. 1997, Dudek et al. 1997).

5                   Analysis of Akt levels in human tumors showed that Akt2 is overexpressed in a significant number of ovarian (J. Q. Cheung *et al. Proc. Natl. Acad. Sci. U.S.A.* 89:9267-9271(1992)) and pancreatic cancers (J. Q. Cheung *et al. Proc. Natl. Acad. Sci. U.S.A.* 93:3636-3641 (1996)). Similarly, Akt3 was found to be overexpressed in breast and prostate cancer cell lines (Nakatani et al. *J. Biol. Chem.* 10 274:21528-21532 (1999).

                  The tumor suppressor PTEN, a protein and lipid phosphatase that specifically removes the 3' phosphate of PtdIns(3,4,5)-P3, is a negative regulator of the PI3K/Akt pathway (Li et al. *Science* 275:1943-1947 (1997), Stambolic et al. *Cell* 95:29-39 (1998), Sun et al. *Proc. Natl. Acad. Sci. U.S.A.* 96:6199-6204 (1999)).  
15   Germline mutations of PTEN are responsible for human cancer syndromes such as Cowden disease (Liaw et al. *Nature Genetics* 16:64-67 (1997)). PTEN is deleted in a large percentage of human tumors and tumor cell lines without functional PTEN show elevated levels of activated Akt (Li et al. *supra*, Guldberg et al. *Cancer Research* 57:3660-3663 (1997), Risinger et al. *Cancer Research* 57:4736-4738  
20   (1997)).

                  These observations demonstrate that the PI3K/Akt pathway plays important roles for regulating cell survival or apoptosis in tumorigenesis.

                  Three members of the Akt/PKB subfamily of second-messenger regulated serine/threonine protein kinases have been identified and termed  
25   Akt1/PKB $\alpha$ , Akt2/PKB $\beta$ , and Akt3/PKB $\gamma$ , respectively. The isoforms are homologous, particularly in regions encoding the catalytic domains. Akt/PKBs are activated by phosphorylation events occurring in response to PI3K signaling. PI3K phosphorylates membrane inositol phospholipids, generating the second messengers phosphatidyl-inositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-bisphosphate,  
30   which have been shown to bind to the PH domain of Akt/PKB. The current model of Akt/PKB activation proposes recruitment of the enzyme to the membrane by 3'-phosphorylated phosphoinositides, where phosphorylation of the regulatory sites of Akt/PKB by the upstream kinases occurs (B.A. Hemmings, *Science* 275:628-630

(1997); B.A. Hemmings, *Science* 276:534 (1997); J. Downward, *Science* 279:673-674 (1998)).

Phosphorylation of Akt1/PKB $\alpha$  occurs on two regulatory sites, Thr<sup>308</sup> in the catalytic domain activation loop and on Ser<sup>473</sup> near the carboxy terminus (D. R. Alessi *et al.* *EMBO J.* 15:6541-6551 (1996) and R. Meier *et al.* *J. Biol. Chem.* 272:30491-30497 (1997)). Equivalent regulatory phosphorylation sites occur in Akt2/PKB $\beta$  and Akt3/PKB $\gamma$ . The upstream kinase, which phosphorylates Akt/PKB at the activation loop site has been cloned and termed 3'-phosphoinositide-dependent protein kinase 1 (PDK1). PDK1 phosphorylates not only Akt/PKB, but also p70 ribosomal S6 kinase, p90RSK, serum and glucocorticoid-regulated kinase (SGK), and protein kinase C. The upstream kinase phosphorylating the regulatory site of Akt/PKB near the carboxy terminus has not been identified yet, but recent reports imply a role for the integrin-linked kinase (ILK-1), a serine/threonine protein kinase, or autophosphorylation.

Inhibition of Akt activation and activity can be achieved by inhibiting PI3K with inhibitors such as LY294002 and wortmannin. However, PI3K inhibition has the potential to indiscriminately affect not just all three Akt isozymes but also other PH domain-containing signaling molecules that are dependent on PtdIns(3,4,5)-P3, such as the Tec family of tyrosine kinases. Furthermore, it has been disclosed that Akt can be activated by growth signals that are independent of PI3K.

Alternatively, Akt activity can be inhibited by blocking the activity of the upstream kinase PDK1. No specific PDK1 inhibitors have been disclosed. Again, inhibition of PDK1 would result in inhibition of multiple protein kinases whose activities depend on PDK1, such as atypical PKC isoforms, SGK, and S6 kinases (Williams *et al.* *Curr. Biol.* 10:439-448 (2000)).

It is an object of the instant invention to provide novel compounds that are inhibitors of Akt/PKB.

It is also an object of the present invention to provide pharmaceutical compositions that comprise.


It is also an object of the present invention to provide a method for treating cancer that comprises administering such inhibitors of Akt/PKB activity.

## SUMMARY OF THE INVENTION

The instant invention provides for compounds which comprise a 2,3-diphenylquinoxaline moiety that inhibit of Akt/PKB activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt/PKB isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt/PKB activity by administering the compound to a patient in need of treatment of cancer.

## DETAILED DESCRIPTION OF THE INVENTION

The compounds of the instant invention are useful in the inhibition of the activity of the serine/threonine kinase Akt. In a first embodiment of this invention, the inhibitors of Akt activity are illustrated by the formula A:



wherein:

a is 0 or 1;

b is 0 or 1;

20 m is 0, 1 or 2;

n is 0, 1, 2 or 3;

p is 0, 1 or 2;

r is 0 or 1;

s is 0 or 1;

25 t is 2, 3, 4, 5 or 6;

u, v, w and x are independently selected from: CH and N;

y and z are independently selected from: CH and N, provided that at least one of y and z is N;

5 R<sup>1</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,
- 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 10 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,
- 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 7) CO<sub>2</sub>H,
- 8) halo,
- 9) CN,
- 15 10) OH,
- 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,
- 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>7</sup>R<sup>8</sup>,
- 13) NR<sup>c</sup>(C=O)NR<sup>7</sup>R<sup>8</sup>,
- 14) S(O)<sub>m</sub>R<sup>a</sup>,
- 20 15) S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>,
- 16) NR<sup>c</sup>S(O)<sub>m</sub>R<sup>a</sup>,
- 17) oxo,
- 18) CHO,
- 19) NO<sub>2</sub>,
- 25 20) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,
- 21) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 22) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 23) O(C=O)O<sub>b</sub>aryl, and
- 24) O(C=O)O<sub>b</sub>-heterocycle,

30 said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R<sup>z</sup>;

R<sup>2</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 35 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,

- 5 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,  
 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,  
 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,  
 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 7) CO<sub>2</sub>H,  
 8) halo,  
 9) CN,  
 10) OH,  
 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,  
 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>7</sup>R<sup>8</sup>,  
 13) NR<sup>c</sup>(C=O)NR<sup>7</sup>R<sup>8</sup>,  
 14) S(O)<sub>m</sub>R<sup>a</sup>,  
 15) S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>,  
 16) NR<sup>c</sup>S(O)<sub>m</sub>R<sup>a</sup>,  
 17) CHO,  
 18) NO<sub>2</sub>,  
 19) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,  
 20) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,  
 21) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 22) O(C=O)O<sub>b</sub>aryl, and  
 23) O(C=O)O<sub>b</sub>-heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R<sup>Z</sup>;

- 25 R<sup>3</sup> and R<sup>4</sup> are independently selected from: H, C<sub>1</sub>-C<sub>6</sub>-alkyl and C<sub>1</sub>-C<sub>6</sub>-perfluoroalkyl, or

R<sup>3</sup> and R<sup>4</sup> are combined to form -(CH<sub>2</sub>)<sub>t</sub> wherein one of the carbon atoms is optionally replaced by a moiety selected from O, S(O)<sub>m</sub>, -N(R<sup>b</sup>)C(O)-, and

- 30 -N(COR<sup>a</sup>)-;

R<sup>5</sup> is independently selected from:

- 1) H,  
 2) (C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,



- 3) (C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 4) (C=O)O<sub>b</sub>aryl,  
 5) (C=O)O<sub>b</sub>heterocyclyl,  
 6) C<sub>1</sub>-C<sub>10</sub> alkyl,  
 5 7) aryl,  
 8) C<sub>2</sub>-C<sub>10</sub> alkenyl,  
 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,  
 10) heterocyclyl,  
 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 10 12) SO<sub>2</sub>R<sup>a</sup>, and  
 13) (C=O)NR<sup>b</sup><sub>2</sub>,
- said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>z</sup>;
- 15 R<sup>6</sup> is NR<sup>7</sup>R<sup>8</sup>, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, noboranyl, aryl, 2,2,2-trifluoroethyl, benzyl or heterocyclyl, said alkyl, cycloalkyl, noboranyl, aryl, heterocyclyl and benzyl is optionally substituted with one or more substituents selected from R<sup>z</sup>;
- 20 R<sup>7</sup> and R<sup>8</sup> are independently selected from:
- 1) H,  
 2) (C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,  
 3) (C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 4) (C=O)O<sub>b</sub>aryl,  
 25 5) (C=O)O<sub>b</sub>heterocyclyl,  
 6) C<sub>1</sub>-C<sub>10</sub> alkyl,  
 7) aryl,  
 8) C<sub>2</sub>-C<sub>10</sub> alkenyl,  
 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,  
 30 10) heterocyclyl,  
 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 12) SO<sub>2</sub>R<sup>a</sup>, and  
 13) (C=O)NR<sup>b</sup><sub>2</sub>,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from  $R^Z$ , or

- 5  $R^7$  and  $R^8$  can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from  $R^Z$ ;

- 10  $R^Z$  is selected from:
- 1)  $(C=O)_r O_s (C_1-C_{10})$ alkyl,
  - 2)  $O_r (C_1-C_3)$ perfluoroalkyl,
  - 3)  $(C_0-C_6)$ alkylene-S(O) $_m R^a$ ,
  - 4) oxo,
  - 15 5) OH,
  - 6) halo,
  - 7) CN,
  - 8)  $(C=O)_r O_s (C_2-C_{10})$ alkenyl,
  - 9)  $(C=O)_r O_s (C_2-C_{10})$ alkynyl,
  - 20 10)  $(C=O)_r O_s (C_3-C_6)$ cycloalkyl,
  - 11)  $(C=O)_r O_s (C_0-C_6)$ alkylene-aryl,
  - 12)  $(C=O)_r O_s (C_0-C_6)$ alkylene-heterocyclyl,
  - 13)  $(C=O)_r O_s (C_0-C_6)$ alkylene-N( $R^b$ ) $_2$ ,
  - 14) C(O) $R^a$ ,
  - 25 15)  $(C_0-C_6)$ alkylene-CO $_2 R^a$ ,
  - 16) C(O)H,
  - 17)  $(C_0-C_6)$ alkylene-CO $_2 H$ ,
  - 18) C(O)N( $R^b$ ) $_2$ ,
  - 19) S(O) $_m R^a$ ,
  - 30 20) S(O) $_2 N(R^b)_2$
  - 21) NR $^c$ (C=O)O $_b R^a$ ,
  - 22) O(C=O)O $_b C_1-C_{10}$  alkyl,
  - 23) O(C=O)O $_b C_3-C_8$  cycloalkyl,
  - 24) O(C=O)O $_b$ aryl, and

25)  $O(C=O)O_b$ -heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from  $R^b$ , OH,  $(C_1-C_6)$ alkoxy, halogen,  $CO_2H$ , CN,  $O(C=O)C_1-C_6$  alkyl, oxo, and  $N(R^b)_2$ ;

5

$R^a$  is  $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_2-C_6)$ alkynyl,  $(C_3-C_6)$ cycloalkyl, substituted or unsubstituted aryl,  $(C_1-C_6)$ perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

10  $R^b$  is H,  $(C_1-C_6)$ alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl,  $(C_3-C_6)$ cycloalkyl,  $(C=O)OC_1-C_6$  alkyl,  $(C=O)C_1-C_6$  alkyl or  $S(O)_2R^a$ ;

$R^c$  is selected from:

- 15           1) H,  
              2)  $C_1-C_{10}$  alkyl,  
              3) aryl,  
              4)  $C_2-C_{10}$  alkenyl,  
              5)  $C_2-C_{10}$  alkynyl,  
              6) heterocyclyl,  
 20           7)  $C_3-C_8$  cycloalkyl,  
              8)  $C_1-C_6$  perfluoroalkyl,


said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from  $R^Z$ , or

25

or a pharmaceutically acceptable salt or a stereoisomer thereof.

In another embodiment the inhibitors of the instant invention are illustrated by the formula B:

30



wherein:

- 5    n is 0, 1, 2 or 3;  
      p is 0, 1 or 2;  
      r is 0 or 1;  
      s is 0 or 1;
- 10   u, v, w and x are independently selected from: CH and N, provided that only one of u, v, w and x may be N;
- R<sup>1</sup> is independently selected from:
- 15    1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,  
      2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,  
      3) C<sub>2</sub>-C<sub>10</sub> alkenyl,  
      4) C<sub>2</sub>-C<sub>10</sub> alkynyl,  
      5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,  
      6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
      7) CO<sub>2</sub>H,  
      8) halo,  
      9) CN,  
      10) OH,  
      11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,  
      12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>7</sup>R<sup>8</sup>,  
      13) NR<sup>c</sup>(C=O)NR<sup>7</sup>R<sup>8</sup>,  
      14) S(O)<sub>m</sub>R<sup>a</sup>,
- 20    25

- 5
- 15)  $S(O)_2NR^7R^8$ ,
  - 16)  $NR^cS(O)_mR^a$ ,
  - 17) oxo,
  - 18) CHO,
  - 19)  $NO_2$ ,
  - 20)  $NR^c(C=O)O_bR^a$ ,
  - 21)  $O(C=O)O_bC_1-C_{10}$  alkyl,
  - 22)  $O(C=O)O_bC_3-C_8$  cycloalkyl,
  - 23)  $O(C=O)O_b$ aryl, and
  - 10 24)  $O(C=O)O_b$ -heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from  $R^Z$ ;

$R^2$  is independently selected from:

- 15
- 1)  $(C=O)_aO_bC_1-C_{10}$  alkyl,
  - 2)  $(C=O)_aO_b$ aryl,
  - 3)  $C_2-C_{10}$  alkenyl,
  - 4)  $C_2-C_{10}$  alkynyl,
  - 5)  $(C=O)_aO_b$  heterocyclyl,
  - 20 6)  $(C=O)_aO_bC_3-C_8$  cycloalkyl,
  - 7)  $CO_2H$ ,
  - 8) halo,
  - 9) CN,
  - 10) OH,
  - 25 11)  $O_bC_1-C_6$  perfluoroalkyl,
  - 12)  $O_a(C=O)_bNR^7R^8$ ,
  - 13)  $NR^c(C=O)NR^7R^8$ ,
  - 14)  $S(O)_mR^a$ ,
  - 15)  $S(O)_2NR^7R^8$ ,
  - 30 16)  $NR^cS(O)_mR^a$ ,
  - 17) CHO,
  - 18)  $NO_2$ ,
  - 19)  $NR^c(C=O)O_bR^a$ ,
  - 20)  $O(C=O)O_bC_1-C_{10}$  alkyl,

- 21)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$  cycloalkyl,
- 22)  $\text{O}(\text{C}=\text{O})\text{O}_b$ aryl, and
- 23)  $\text{O}(\text{C}=\text{O})\text{O}_b$ -heterocycle,

5 said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from  $\text{R}^Z$ ;

$\text{R}^5$  is independently selected from:

- 1) H,
- 2)  $(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$  alkyl,
- 10 3)  $(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$  cycloalkyl,
- 4)  $(\text{C}=\text{O})\text{O}_b$ aryl,
- 5)  $(\text{C}=\text{O})\text{O}_b$ heterocyclyl,
- 6)  $\text{C}_1\text{-C}_{10}$  alkyl,
- 7) aryl,
- 15 8)  $\text{C}_2\text{-C}_{10}$  alkenyl,
- 9)  $\text{C}_2\text{-C}_{10}$  alkynyl,
- 10) heterocyclyl,
- 11)  $\text{C}_3\text{-C}_8$  cycloalkyl,
- 12)  $\text{SO}_2\text{R}^a$ , and
- 20 13)  $(\text{C}=\text{O})\text{NR}^b_2$ ,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from  $\text{R}^Z$ ;

25  $\text{R}^6$  is  $\text{NR}^7\text{R}^8$ ,  $(\text{C}_1\text{-C}_6)$ alkyl,  $(\text{C}_1\text{-C}_6)$ perfluoroalkyl,  $(\text{C}_3\text{-C}_6)$ cycloalkyl, noboranyl, aryl, 2,2,2-trifluoroethyl, benzyl or heterocyclyl, said alkyl, cycloalkyl, noboranyl, aryl, heterocyclyl and benzyl is optionally substituted with one or more substituents selected from  $\text{R}^Z$ ;

$\text{R}^7$  and  $\text{R}^8$  are independently selected from:

- 30 1) H,
- 2)  $(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$  alkyl,
- 3)  $(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$  cycloalkyl,
- 4)  $(\text{C}=\text{O})\text{O}_b$ aryl,
- 5)  $(\text{C}=\text{O})\text{O}_b$ heterocyclyl,

- 5
- 6) C<sub>1</sub>-C<sub>10</sub> alkyl,
  - 7) aryl,
  - 8) C<sub>2</sub>-C<sub>10</sub> alkenyl,
  - 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,
  - 10) heterocyclyl,
  - 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
  - 12) SO<sub>2</sub>R<sup>a</sup>, and
  - 13) (C=O)NR<sup>b</sup><sub>2</sub>,

10 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

15 R<sup>7</sup> and R<sup>8</sup> can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>Z</sup> is selected from:

- 20
- 1) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,
  - 2) O<sub>r</sub>(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkyl,
  - 3) (C<sub>0</sub>-C<sub>6</sub>)alkylene-S(O)<sub>m</sub>R<sup>a</sup>,
  - 4) oxo,
  - 5) OH,
  - 6) halo,
  - 25 7) CN,
  - 8) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkenyl,
  - 9) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkynyl,
  - 10) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
  - 11) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-aryl,
  - 30 12) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-heterocyclyl,
  - 13) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-N(R<sup>b</sup>)<sub>2</sub>,
  - 14) C(O)R<sup>a</sup>,
  - 15) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>R<sup>a</sup>,
  - 16) C(O)H,

- 17) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>H,  
 18) C(O)N(R<sup>b</sup>)<sub>2</sub>,  
 19) S(O)<sub>m</sub>R<sup>a</sup>,  
 20) S(O)<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>  
 5 21) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,  
 22) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,  
 23) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 24) O(C=O)O<sub>b</sub>aryl, and  
 25) O(C=O)O<sub>b</sub>-heterocycle,  
 10 said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R<sup>b</sup>, OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen, CO<sub>2</sub>H, CN, O(C=O)C<sub>1</sub>-C<sub>6</sub> alkyl, oxo, and N(R<sup>b</sup>)<sub>2</sub>;

R<sup>a</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
 15 substituted or unsubstituted aryl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

R<sup>b</sup> is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)OC<sub>1</sub>-C<sub>6</sub>  
 20 alkyl, (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl or S(O)<sub>2</sub>R<sup>a</sup>;

R<sup>c</sup> is selected from:


- 1) H,  
 2) C<sub>1</sub>-C<sub>10</sub> alkyl,  
 25 3) aryl,  
 4) C<sub>2</sub>-C<sub>10</sub> alkenyl,  
 5) C<sub>2</sub>-C<sub>10</sub> alkynyl,  
 6) heterocyclyl,  
 7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 30 8) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>z</sup>, or

or a pharmaceutically acceptable salt or a stereoisomer thereof.



In another embodiment the inhibitors of the instant invention are illustrated by the formula B:



wherein:

n is 0, 1, 2 or 3;

p is 0, 1 or 2;

r is 0 or 1;

s is 0 or 1;

u, v, w and x are independently selected from: CH and N, provided that only one of u, v, w and x may be N;

R<sup>1</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,
- 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,
- 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 7) CO<sub>2</sub>H,
- 8) halo,
- 9) CN,
- 10) OH,
- 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

- 12)  $O_a(C=O)_bNR^7R^8$ ,  
 13)  $NR^c(C=O)NR^7R^8$ ,  
 14)  $S(O)_mR^a$ ,  
 15)  $S(O)_2NR^7R^8$ ,  
 5 16)  $NR^cS(O)_mR^a$ ,  
 17) oxo,  
 18) CHO,  
 19) NO<sub>2</sub>,  
 20)  $NR^c(C=O)O_bR^a$ ,  
 10 21)  $O(C=O)O_bC_1-C_{10}$  alkyl,  
 22)  $O(C=O)O_bC_3-C_8$  cycloalkyl,  
 23)  $O(C=O)O_b$ aryl, and  
 24)  $O(C=O)O_b$ -heterocycle,

15 said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>2</sup> is independently selected from:

- 1) C<sub>1</sub>-C<sub>6</sub> alkyl,  
 2) aryl,  
 20 3) heterocyclyl,  
 4) CO<sub>2</sub>H,  
 5) halo,  
 6) CN,  
 7) OH,  
 25 8)  $S(O)_2NR^7R^8$ ,

said alkyl, aryl and heterocyclyl optionally substituted with one, two or three substituents selected from R<sup>Z</sup>;

R<sup>5</sup> is independently selected from:

- 30 1) H,  
 2) C<sub>1</sub>-C<sub>10</sub> alkyl,  
 3) aryl, and  
 4) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,

said alkyl, cycloalkyl and aryl is optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>6</sup> is NR<sup>7</sup>R<sup>8</sup>, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, noboranyl, aryl, 2,2,2-trifluoroethyl, benzyl or heterocyclyl, said alkyl, cycloalkyl, noboranyl, aryl, heterocyclyl and benzyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>7</sup> and R<sup>8</sup> are independently selected from:

- 1) H,
- 2) (C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) (C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 4) (C=O)O<sub>b</sub>aryl,
- 5) (C=O)O<sub>b</sub>heterocyclyl,
- 6) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 7) aryl,
- 8) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 10) heterocyclyl,
- 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 12) SO<sub>2</sub>R<sup>a</sup>, and
- 13) (C=O)NR<sup>b</sup><sub>2</sub>.

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

R<sup>Z</sup> is selected from:

- 1) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,
- 2) O<sub>r</sub>(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkyl,
- 3) (C<sub>0</sub>-C<sub>6</sub>)alkylene-S(O)<sub>m</sub>R<sup>a</sup>,
- 4) oxo,
- 5) OH,
- 6) halo,
- 7) CN,
- 8) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkenyl,

- 9)  $(C=O)_rO_s(C_2-C_{10})alkynyl$ ,  
 10)  $(C=O)_rO_s(C_3-C_6)cycloalkyl$ ,  
 11)  $(C=O)_rO_s(C_0-C_6)alkylene-aryl$ ,  
 12)  $(C=O)_rO_s(C_0-C_6)alkylene-heterocyclyl$ ,  
 5 13)  $(C=O)_rO_s(C_0-C_6)alkylene-N(R^b)_2$ ,  
 14)  $C(O)R^a$ ,  
 15)  $(C_0-C_6)alkylene-CO_2R^a$ ,  
 16)  $C(O)H$ ,  
 17)  $(C_0-C_6)alkylene-CO_2H$ ,  
 10 18)  $C(O)N(R^b)_2$ ,  
 19)  $S(O)_mR^a$ , and  
 20)  $S(O)_2NR^9R^{10}$   
 21)  $NR^c(C=O)O_bR^a$ ,  
 22)  $O(C=O)O_bC_1-C_{10} alkyl$ ,  
 15 23)  $O(C=O)O_bC_3-C_8 cycloalkyl$ ,  
 24)  $O(C=O)O_baryl$ , and  
 25)  $O(C=O)O_b-heterocycle$ ,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from  $R^b$ , OH,  $(C_1-C_6)alkoxy$ , halogen,  $CO_2H$ ,  
 20 CN,  $O(C=O)C_1-C_6 alkyl$ , oxo, and  $N(R^b)_2$ ;

$R^a$  is  $(C_1-C_6)alkyl$ ,  $(C_3-C_6)cycloalkyl$ , substituted or unsubstituted aryl, or heterocyclyl; and

- 25  $R^b$  is H,  $(C_1-C_6)alkyl$ , substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl,  $(C_3-C_6)cycloalkyl$ ,  $(C=O)OC_1-C_6 alkyl$ ,  $(C=O)C_1-C_6 alkyl$  or  $S(O)_2R^a$ ;

$R^c$  is selected from:

- 30 1) H,  
 2)  $C_1-C_{10} alkyl$ ,  
 3) aryl,  
 4)  $C_2-C_{10} alkenyl$ ,  
 5)  $C_2-C_{10} alkynyl$ ,

- 6) heterocyclyl,
- 7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 8) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

5 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or


or a pharmaceutically acceptable salt or a stereoisomer thereof.


A specific compound of the instant invention is:

10 N-[4-(3-phenylquinoxalin-2-yl)benzyl]propane-1-sulfonamide.

15 The compounds of the present invention may have asymmetric centers, chiral axes, and chiral planes (as described in: E.L. Eliel and S.H. Wilen, *Stereochemistry of Carbon Compounds*, John Wiley & Sons, New York, 1994, pages 1119-1190), and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers and mixtures thereof, including optical isomers, all such stereoisomers being included in the present invention.

20 In addition, the compounds disclosed herein may exist as tautomers and both tautomeric forms are intended to be encompassed by the scope of the invention, even though only one tautomeric structure is depicted. For example, any claim to compound A below is understood to include tautomeric structure B, and vice versa, as well as mixtures thereof. The two tautomeric forms of the benzimidazolonyl moiety are also within the scope of the instant invention.





When any variable (e.g. R<sup>1</sup>, R<sup>2</sup>, R<sup>Z</sup>, etc.) occurs more than one time in any constituent, its definition on each occurrence is independent at every other occurrence. Also, combinations of substituents and variables are permissible only if such combinations result in stable compounds. Lines drawn into the ring systems from substituents represent that the indicated bond may be attached to any of the substitutable ring atoms. If the ring system is polycyclic, it is intended that the bond be attached to any of the suitable carbon atoms on the proximal ring only.

It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results. The phrase "optionally substituted with one or more substituents" should be taken to be equivalent to the phrase "optionally substituted with at least one substituent" and in such cases the preferred embodiment will have from zero to three substituents.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, C<sub>1</sub>-C<sub>10</sub>, as in "C<sub>1</sub>-C<sub>10</sub> alkyl" is defined to include groups having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons in a linear or branched arrangement. For example, "C<sub>1</sub>-C<sub>10</sub> alkyl" specifically includes methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *t*-butyl, *i*-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and so on. The term "cycloalkyl" means a monocyclic saturated aliphatic hydrocarbon group having the specified number of carbon atoms. For example, "cycloalkyl" includes cyclopropyl, methyl-cyclopropyl, 2,2-dimethyl-cyclobutyl, 2-ethyl-cyclopentyl, cyclohexyl, and so on.

"Alkoxy" represents either a cyclic or non-cyclic alkyl group of indicated number of carbon atoms attached through an oxygen bridge. "Alkoxy" therefore encompasses the definitions of alkyl and cycloalkyl above.

If no number of carbon atoms is specified, the term "alkenyl" refers to a non-aromatic hydrocarbon radical, straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. Preferably one carbon to carbon double bond is present, and up to four non-aromatic carbon-carbon double bonds may be present. Thus, "C<sub>2</sub>-C<sub>6</sub> alkenyl" means an alkenyl radical having from 2 to 6 carbon atoms. Alkenyl groups include ethenyl, propenyl, butenyl, 2-methylbutenyl and cyclohexenyl. The straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated.

The term "alkynyl" refers to a hydrocarbon radical straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon triple bond. Up to three carbon-carbon triple bonds may be present. Thus, "C<sub>2</sub>-C<sub>6</sub> alkynyl" means an alkynyl radical having from 2 to 6 carbon atoms. Alkynyl groups include ethynyl, propynyl, butynyl, 3-methylbutynyl and so on. The straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated.

In certain instances, substituents may be defined with a range of carbons that includes zero, such as (C<sub>0</sub>-C<sub>6</sub>)alkylene-aryl. If aryl is taken to be phenyl, this definition would include phenyl itself as well as -CH<sub>2</sub>Ph, -CH<sub>2</sub>CH<sub>2</sub>Ph, CH(CH<sub>3</sub>)CH<sub>2</sub>CH(CH<sub>3</sub>)Ph, and so on.

As used herein, "aryl" is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 atoms in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl and biphenyl. In cases where the aryl substituent is bicyclic and one ring is non-aromatic, it is understood that attachment is via the aromatic ring.

The term heteroaryl, as used herein, represents a stable monocyclic or bicyclic ring of up to 7 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms selected from the group consisting of O, N and S. Heteroaryl groups within the scope of this definition include but are not limited to: acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, pyrazolyl, indolyl, benzotriazolyl, furanyl, thienyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, indolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl,

tetrahydroquinoline. As with the definition of heterocycle below, "heteroaryl" is also understood to include the N-oxide derivative of any nitrogen-containing heteroaryl. In cases where the heteroaryl substituent is bicyclic and one ring is non-aromatic or contains no heteroatoms, it is understood that attachment is via the aromatic ring or via the heteroatom containing ring, respectively. Such heteroaryl moieties for substituent Q include but are not limited to: 2-benzimidazolyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 1-isoquinolinyl, 3-isoquinolinyl and 4-isoquinolinyl.

The term "heterocycle" or "heterocyclyl" as used herein is intended to mean a 5- to 10-membered aromatic or nonaromatic heterocycle containing from 1 to 4 heteroatoms selected from the group consisting of O, N and S, and includes bicyclic groups. "Heterocyclyl" therefore includes the above mentioned heteroaryls, as well as dihydro and tetrahydro analogs thereof. Further examples of "heterocyclyl" include, but are not limited to the following: benzoimidazolyl, benzoimidazolonyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolaziny, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazoliny, quinolyl, quinoxaliny, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidiny, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidiny, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof. Attachment of a heterocyclyl substituent can occur via a carbon atom or via a heteroatom.


Preferably, heterocycle is selected from 2-azepinone, benzimidazolyl, 2-diazapinone, imidazolyl, 2-imidazolidinone, indolyl, isoquinolinyl, morpholinyl, piperidyl, piperazinyl, pyridyl, pyrrolidinyl, 2-piperidinone, 2-pyrimidinone, 2-pyrrolidinone, quinolinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, and thienyl.




As appreciated by those of skill in the art, "halo" or "halogen" as used herein is intended to include chloro, fluoro, bromo and iodo.

- As used herein, unless otherwise specifically defined, substituted alkyl, substituted cycloalkyl, substituted aroyl, substituted aryl, substituted heteroaroyl, substituted heteroaryl, substituted arylsulfonyl, substituted heteroaryl-sulfonyl and substituted heterocycle include moieties containing from 1 to 3 substituents in addition to the point of attachment to the rest of the compound. Preferably, such substituents are selected from the group which includes but is not limited to F, Cl, Br, CF<sub>3</sub>, NH<sub>2</sub>, N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub> alkyl)O-, (aryl)O-, -OH, (C<sub>1</sub>-C<sub>6</sub> alkyl)S(O)<sub>m</sub>-, (C<sub>1</sub>-C<sub>6</sub> alkyl)C(O)NH-, H<sub>2</sub>N-C(NH)-, (C<sub>1</sub>-C<sub>6</sub> alkyl)C(O)-, (C<sub>1</sub>-C<sub>6</sub> alkyl)OC(O)-, (C<sub>1</sub>-C<sub>6</sub> alkyl)OC(O)NH-, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, isothiazolyl and C<sub>1</sub>-C<sub>20</sub> alkyl. For example, a (C<sub>1</sub>-C<sub>6</sub>)alkyl may be substituted with one, two or three substituents selected from OH, oxo, halogen, alkoxy, dialkylamino, or heterocyclyl, such as morpholinyl, piperidinyl, and so on. In this case, if one substituent is oxo and the other is OH, the following are included in the definition: -C(=O)CH<sub>2</sub>CH(OH)CH<sub>3</sub>, -(C=O)OH, -CH<sub>2</sub>(OH)CH<sub>2</sub>CH(O), and so on.


The moiety illustrated by the formula:



includes the following structures, which are meant to be merely illustrative and not limiting:




Preferably, the moiety illustrated by the formula:




5

is selected from:




The moieties form when R<sup>1</sup> is oxo include the following structures, which are meant to be merely illustrative and not limiting:

5




The moiety formed when, in the definition of R<sup>3</sup> and R<sup>4</sup> on the same carbon atom are combined to form -(CH<sub>2</sub>)<sub>t</sub>- is illustrated by the following:

10




In addition, such cyclic moieties may optionally include a heteroatom(s). Examples of such heteroatom-containing cyclic moieties include, but are not limited to:



5

In certain instances, R<sup>7</sup> and R<sup>8</sup> are defined such that they can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said heterocycle optionally substituted with one or more substituents selected from R<sup>Z</sup>. Examples of the heterocycles that can thus be formed include, but are not limited to the following, keeping in mind that the heterocycle is optionally substituted with one or more (and preferably one, two or three) substituents chosen from R<sup>Z</sup>:

15



Preferably, y and z are N.

Preferably R<sup>1</sup> is selected from: halogen, -OH, -CN, -NO<sub>2</sub>, -CF<sub>3</sub>, -OC<sub>1</sub>-

- 5 C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, heterocyclyl, SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub> alkyl, -NRC<sub>1</sub>SO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub> alkyl, -CO<sub>2</sub>H, (C=O)OC<sub>1</sub>-C<sub>6</sub>alkyl, -(C=O)NR<sup>7</sup>R<sup>8</sup>, -(C=O)aryl, SO<sub>2</sub>aryl and SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, optionally substituted with one to three substituents selected from R<sup>z</sup>. More preferably, R<sup>1</sup> is -OH, -OC<sub>1</sub>-C<sub>6</sub>alkyl, -CO<sub>2</sub>H, -(C=O)NR<sup>7</sup>R<sup>8</sup> and C<sub>1</sub>-C<sub>6</sub>alkyl.

Preferably  $R^2$  is selected from  $C_1$ - $C_6$ alkyl, -OH, - $OC_1$ - $C_6$ alkyl, - $CF_3$ , CN and halogen, optionally substituted with one substituent selected from  $R^Z$ .

Also preferred is the definition of  $R^3$  and  $R^4$  selected from H and - $CH_3$ . More preferred  $R^3$  and  $R^4$  are H.

5 Preferably  $R^5$  is selected from H and  $C_1$ - $C_6$  alkyl. More preferably  $R^5$  is H.

Preferably  $R^7$  and  $R^8$  are selected from H,  $C_1$ - $C_6$  alkyl and aryl, optionally substituted with one to two substituents selected from  $R^Z$ . More preferably,  $R^7$  and  $R^8$  are selected from H or  $C_1$ - $C_6$  alkyl.

10 Included in the instant invention is the free form of compounds of Formula A, as well as the pharmaceutically acceptable salts and stereoisomers thereof. Some of the isolated specific compounds exemplified herein are the protonated salts of amine compounds. The term "free form" refers to the amine compounds in non-salt form. The encompassed pharmaceutically acceptable salts not  
15 only include the isolated salts exemplified for the specific compounds described herein, but also all the typical pharmaceutically acceptable salts of the free form of compounds of Formula A. The free form of the specific salt compounds described may be isolated using techniques known in the art. For example, the free form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as  
20 dilute aqueous NaOH, potassium carbonate, ammonia and sodium bicarbonate. The free forms may differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise pharmaceutically equivalent to their respective free forms for purposes of the invention.

25 The pharmaceutically acceptable salts of the instant compounds can be synthesized from the compounds of this invention which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts of the basic compounds are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming  
30 inorganic or organic acid in a suitable solvent or various combinations of solvents. Similarly, the salts of the acidic compounds are formed by reactions with the appropriate inorganic or organic base.

Thus, pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention

as formed by reacting a basic instant compound with an inorganic or organic acid. For example, conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, as well as salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.

When the compound of the present invention is acidic, suitable "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.

The preparation of the pharmaceutically acceptable salts described above and other typical pharmaceutically acceptable salts is more fully described by Berg *et al.*, "Pharmaceutical Salts," *J. Pharm. Sci.*, 1977:66:1-19.

It will also be noted that the compounds of the present invention are potentially internal salts or zwitterions, since under physiological conditions a deprotonated acidic moiety in the compound, such as a carboxyl group, may be anionic, and this electronic charge might then be balanced off internally against the cationic charge of a protonated or alkylated basic moiety, such as a quaternary nitrogen atom.

The compounds of the instant invention are inhibitors of the activity of Akt and are thus useful in the treatment of cancer, in particular cancers associated

with irregularities in the activity of Akt and/or GSK3. Such cancers include, but are not limited to ovarian, pancreatic and breast cancer.

In an embodiment of the invention, the instant compound is a selective inhibitor whose inhibitory efficacy is dependent on the PH domain. In this  
5 embodiment, the compound exhibits a decrease in *in vitro* inhibitory activity or no *in vitro* inhibitory activity against truncated Akt proteins lacking the PH domain.

In a further embodiment, the instant compound is selected from the group of a selective inhibitor of Akt 1, a selective inhibitor of Akt 2 and a selective inhibitor of both Akt 1 and Akt 2.

10 In another embodiment, the instant compound is selected from the group of a selective inhibitor of Akt 1, a selective inhibitor of Akt 2, a selective inhibitor of Akt3 and a selective inhibitor of two of the three Akt isoforms.

In another embodiment, the instant compound is a selective inhibitor of all three Akt isoforms, but is not an inhibitor of one, two or all of such Akt  
15 isoforms that have been modified to delete the PH domain, the hinge region or both the PH domain and the hinge region.

The present invention is further directed to a method of inhibiting Akt activity which comprises administering to a mammal in need thereof a pharmaceutically effective amount of the instant compound.

20 The compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including the intravenous, intramuscular,  
25 intraperitoneal, subcutaneous, rectal and topical routes of administration.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to  
30 any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable  
35 excipients which are suitable for the manufacture of tablets. These excipients may be



for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to mask the unpleasant taste of the drug or delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a water soluble taste masking material such as hydroxypropylmethyl-cellulose or hydroxypropylcellulose, or a time delay material such as ethyl cellulose, cellulose acetate butyrate may be employed.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a

thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as butylated hydroxyanisol or alpha-tocopherol.

5                    Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example  
10                    sweetening, flavoring and coloring agents, may also be present. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

                    The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or  
15                    mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening,  
20                    flavouring agents, preservatives and antioxidants.

                    Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.

                    The pharmaceutical compositions may be in the form of a sterile  
25                    injectable aqueous solutions. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.

                    The sterile injectable preparation may also be a sterile injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase. For example, the active ingredient may be first dissolved in a mixture of soybean oil and  
30                    lecithin. The oil solution then introduced into a water and glycerol mixture and processed to form a microemulsion.

                    The injectable solutions or microemulsions may be introduced into a patient's blood-stream by local bolus injection. Alternatively, it may be advantageous to administer the solution or microemulsion in such a way as to maintain a constant  
35                    circulating concentration of the instant compound. In order to maintain such a

constant concentration, a continuous intravenous delivery device may be utilized. An example of such a device is the Deltec CADD-PLUS™ model 5400 intravenous pump.

5 The pharmaceutical compositions may be in the form of  
a sterile injectable aqueous or oleagenous suspension for intramuscular and  
subcutaneous administration. This suspension may be formulated according to the  
known art using those suitable dispersing or wetting agents and suspending agents  
which have been mentioned above. The sterile injectable preparation may also be a  
sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent  
10 or solvent, for example as a solution in 1,3-butane diol. In addition, sterile, fixed oils  
are conventionally employed as a solvent or suspending medium. For this purpose  
any bland fixed oil may be employed including synthetic mono- or diglycerides. In  
addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compounds of Formula A may also be administered in the form of a  
15 suppositories for rectal administration of the drug. These compositions can be  
prepared by mixing the drug with a suitable non-irritating excipient which is solid at  
ordinary temperatures but liquid at the rectal temperature and will therefore melt in  
the rectum to release the drug. Such materials include cocoa butter, glycerinated  
gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various  
20 molecular weights and fatty acid esters of polyethylene glycol.

For topical use, creams, ointments, jellies, solutions or suspensions,  
etc., containing the compound of Formula A are employed. (For purposes of this  
application, topical application shall include mouth washes and gargles.)

The compounds for the present invention can be administered in  
25 intranasal form via topical use of suitable intranasal vehicles and delivery devices, or  
via transdermal routes, using those forms of transdermal skin patches well known to  
those of ordinary skill in the art. To be administered in the form of a transdermal  
delivery system, the dosage administration will, of course, be continuous rather than  
intermittent throughout the dosage regimen.

30 As used herein, the term "composition" is intended to encompass a  
product comprising the specified ingredients in the specific amounts, as well as any  
product which results, directly or indirectly, from combination of the specific  
ingredients in the specified amounts.

Additionally, the compounds of the instant invention may be  
35 administered to a mammal in need thereof using a gel extrusion mechanism (GEM)

device, such as that described in U.S. Patent No. 4,976,697, filed on December 11, 1990, which is hereby incorporated by reference.

5 The instant compounds may also be co-administered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated.

For example, instant compounds are useful in combination with known anti-cancer agents. Combinations of the presently disclosed compounds with other anti-cancer or chemotherapeutic agents are within the scope of the invention. Examples of such agents can be found in *Cancer Principles and Practice of Oncology* by V.T. Devita and S. Hellman (editors), 6<sup>th</sup> edition (February 15, 2001), Lippincott Williams & Wilkins Publishers. A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the cancer involved. Such anti-cancer agents include the following: estrogen receptor modulators, androgen receptor modulators, retinoid receptor modulators, cytotoxic/cytostatic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors and other angiogenesis inhibitors. The instant compounds are particularly useful when co-administered with radiation therapy.

20 "Estrogen receptor modulators" refers to compounds that interfere or inhibit the binding of estrogen to the receptor, regardless of mechanism. Examples of estrogen receptor modulators include, but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyloxy)phenyl]-2H-1-benzopyran-3-yl)]-phenyl-2,2-dimethylpropanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone, and SH646.

"Androgen receptor modulators" refers to compounds which interfere or inhibit the binding of androgens to the receptor, regardless of mechanism. Examples of androgen receptor modulators include finasteride and other 5 $\alpha$ -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate.

30 "Retinoid receptor modulators" refers to compounds which interfere or inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoic acid,  $\alpha$ -difluoromethylornithine, ILX23-7553, trans-N-(4'-hydroxyphenyl) retinamide, and N-4-carboxyphenyl retinamide.

"Cytotoxic/cytostatic agents" refer to compounds which cause cell death or inhibit cell proliferation primarily by interfering directly with the cell's functioning or inhibit or interfere with cell myosis, including alkylating agents, tumor necrosis factors, intercalators, hypoxia activatable compounds, microtubule inhibitors/microtubule-stabilising agents, inhibitors of mitotic kinesins, anti-metabolites; biological response modifiers; hormonal/anti-hormonal therapeutic agents, haematopoietic growth factors, monoclonal antibody targeted therapeutic agents and topoisomerase inhibitors.

Examples of cytotoxic agents include, but are not limited to, sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis-aminedichloro(2-methyl-pyridine)platinum, benzylguanine, glufosfamide, GPX100, (trans, trans, trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine-platinum(II)]bis[diamine(chloro)platinum (II)]tetrachloride, diarizidinylspermine, arsenic trioxide, 1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplaston, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin, annamycin, galarubicin, elinafide, MEN10755, and 4-demethoxy-3-deamino-3-aziridiny-4-methylsulphonyl-daunorubicin (see WO 00/50032).

An example of a hypoxia activatable compound is tirapazamine.

Examples of microtubule inhibitors/microtubule-stabilising agents include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincal leukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl) benzene sulfonamide, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258, and BMS188797.

Some examples of topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3',4'-O-exo-benzylidene-chartreusin, 9-methoxy-N,N-dimethyl-5-nitropyrzolo[3,4,5-kl]acridine-2-(6H) propanamine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':b,7]indolizino[1,2b]quinoline-10,13(9H,15H)dione,

lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane, 2'-dimethylamino-2'-deoxy-etoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a, 5aB, 8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexahydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]-phenanthridinium, 6,9-bis[(2-aminoethyl)amino]benzo[g]isoguinoline-5,10-dione, 5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine-4-carboxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one, and dimesna.

Examples of inhibitors of mitotic kinesins are described in PCT

15 Publications WO 01/30768 and WO 01/98278.


"Antiproliferative agents" includes antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231, and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2'-methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3-dihydro-benzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea, N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-manno-heptopyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b][1,4]thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo(7.4.1.0.0)-tetradeca-2,4,6-trien-9-yl acetic acid ester, swainsonine, lometrexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D-arabino furanosyl cytosine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and trastuzumab.

Examples of monoclonal antibody targeted therapeutic agents include those therapeutic agents which have cytotoxic agents or radioisotopes attached to a cancer cell specific or target cell specific monoclonal antibody. Examples include Bexxar.

35 "HMG-CoA reductase inhibitors" refers to inhibitors of 3-hydroxy-

3-methylglutaryl-CoA reductase. Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art. For example, see the assays described or cited in U.S. Patent 4,231,938 at col. 6, and WO 84/02131 at pp. 30-33. The terms "HMG-CoA reductase inhibitor" and "inhibitor of HMG-CoA reductase" have the same meaning when used herein.

Examples of HMG-CoA reductase inhibitors that may be used include but are not limited to lovastatin (MEVACOR<sup>®</sup>; see U.S. Patent Nos. 4,231,938, 4,294,926 and 4,319,039), simvastatin (ZOCOR<sup>®</sup>; see U.S. Patent Nos. 4,444,784, 4,820,850 and 4,916,239), pravastatin (PRAVACHOL<sup>®</sup>; see U.S. Patent Nos. 4,346,227, 4,537,859, 4,410,629, 5,030,447 and 5,180,589), fluvastatin (LESCOL<sup>®</sup>; see U.S. Patent Nos. 5,354,772, 4,911,165, 4,929,437, 5,189,164, 5,118,853, 5,290,946 and 5,356,896), atorvastatin (LIPITOR<sup>®</sup>; see U.S. Patent Nos. 5,273,995, 4,681,893, 5,489,691 and 5,342,952) and cerivastatin (also known as rivastatin and BAYCHOL<sup>®</sup>; see US Patent No. 5,177,080). The structural formulas of these and additional HMG-CoA reductase inhibitors that may be used in the instant methods are described at page 87 of M. Yalpani, "Cholesterol Lowering Drugs", *Chemistry & Industry*, pp. 85-89 (5 February 1996) and US Patent Nos. 4,782,084 and 4,885,314. The term HMG-CoA reductase inhibitor as used herein includes all pharmaceutically acceptable lactone and open-acid forms (i.e., where the lactone ring is opened to form the free acid) as well as salt and ester forms of compounds which have HMG-CoA reductase inhibitory activity, and therefor the use of such salts, esters, open-acid and lactone forms is included within the scope of this invention. An illustration of the lactone portion and its corresponding open-acid form is shown below as structures I and II.



In HMG-CoA reductase inhibitors where an open-acid form can exist, salt and ester forms may preferably be formed from the open-acid, and all such forms are included within the meaning of the term "HMG-CoA reductase inhibitor" as used herein. Preferably, the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and most preferably simvastatin. Herein, the term "pharmaceutically acceptable salts" with respect to the HMG-CoA reductase inhibitor shall mean non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base, particularly those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc and tetramethylammonium, as well as those salts formed from amines such as ammonia, ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chlorprocaine, diethanolamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1'-yl-methylbenz-imidazole, diethylamine, piperazine, and tris(hydroxymethyl) aminomethane. Further examples of salt forms of HMG-CoA reductase inhibitors may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamaote, palmitate, panthothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate.

Ester derivatives of the described HMG-CoA reductase inhibitor compounds may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.

"Prenyl-protein transferase inhibitor" refers to a compound which inhibits any one or any combination of the prenyl-protein transferase enzymes, including farnesyl-protein transferase (FPTase), geranylgeranyl-protein transferase type I (GGPTase-I), and geranylgeranyl-protein transferase type-II (GGPTase-II, also called Rab GGPTase). Examples of prenyl-protein transferase inhibiting compounds include (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, (-)-6-[amino(4-



- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone, (+)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1*H*)-quinolinone, 5(S)-*n*-butyl-1-(2,3-dimethylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone, (S)-1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-5-[2-(ethanesulfonyl)methyl]-2-piperazinone, 5(S)-*n*-Butyl-1-(2-methylphenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone, 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-2-methyl-5-imidazolylmethyl]-2-piperazinone, 1-(2,2-diphenylethyl)-3-[N-(1-(4-cyanobenzyl)-1H-imidazol-5-ylethyl)carbamoyl]piperidine, 4-{5-[4-hydroxymethyl]-4-(4-chloropyridin-2-ylmethyl)-piperidine-1-ylmethyl]-2-methylimidazol-1-ylmethyl} benzonitrile, 4-{5-[4-hydroxymethyl-4-(3-chlorobenzyl)-piperidine-1-ylmethyl]-2-methylimidazol-1-ylmethyl} benzonitrile, 4-{3-[4-(2-oxo-2H-pyridin-1-yl)benzyl]-3H-imidazol-4-ylmethyl} benzonitrile, 4-{3-[4-(5-chloro-2-oxo-2H-[1,2']bipyridin-5'-ylmethyl)-3H-imidazol-4-ylmethyl} benzonitrile, 4-{3-[4-(2-oxo-2H-[1,2'] bipyridin-5'-ylmethyl)-3H-imidazol-4-ylmethyl} benzonitrile, 4-[3-(2-oxo-1-phenyl-1,2-dihydropyridin-4-ylmethyl)-3H-imidazol-4-ylmethyl} benzonitrile, 18,19-dihydro-19-oxo-5*H*,17*H*-6,10:12,16-dimetheno-1H-imidazo[4,3-*c*][1,11,4]dioxazacyclo-nonadecine-9-carbonitrile, (±)-19,20-dihydro-19-oxo-5*H*-18,21-ethano-12,14-etheno-6,10-metheno-22*H*-benzo[*d*]imidazo[4,3-*k*][1,6,9,12]oxatriaza-cyclooctadecine-9-carbonitrile, 19,20-dihydro-19-oxo-5*H*,17*H*-18,21-ethano-6,10:12,16-dimetheno-22*H*-imidazo[3,4-*h*][1,8,11,14]oxatriazacycloeicosine-9-carbonitrile, and (±)-19,20-dihydro-3-methyl-19-oxo-5*H*-18,21-ethano-12,14-etheno-6,10-metheno-22*H*-benzo[*d*]imidazo[4,3-*k*][1,6,9,12]oxa-triazacyclooctadecine-9-carbonitrile.
- Other examples of prenyl-protein transferase inhibitors can be found in the following publications and patents: WO 96/30343, WO 97/18813, WO 97/21701, WO 97/23478, WO 97/38665, WO 98/28980, WO 98/29119, WO 95/32987, U.S. Patent No. 5,420,245, U.S. Patent No. 5,523,430, U.S. Patent No. 5,532,359, U.S. Patent No. 5,510,510, U.S. Patent No. 5,589,485, U.S. Patent No. 5,602,098, European Patent Publ. 0 618 221, European Patent Publ. 0 675 112, European Patent Publ. 0 604 181, European Patent Publ. 0 696 593, WO 94/19357, WO 95/08542, WO 95/11917, WO 95/12612, WO 95/12572, WO 95/10514, U.S. Patent No. 5,661,152, WO 95/10515, WO 95/10516, WO 95/24612, WO 95/34535, WO 95/25086, WO 96/05529, WO 96/06138, WO 96/06193, WO 96/16443, WO 96/21701, WO 96/21456, WO 96/22278, WO 96/24611, WO 96/24612,

WO 96/05168, WO 96/05169, WO 96/00736, U.S. Patent No. 5,571,792,  
 WO 96/17861, WO 96/33159, WO 96/34850, WO 96/34851, WO 96/30017,  
 WO 96/30018, WO 96/30362, WO 96/30363, WO 96/31111, WO 96/31477,  
 WO 96/31478, WO 96/31501, WO 97/00252, WO 97/03047, WO 97/03050,  
 5 WO 97/04785, WO 97/02920, WO 97/17070, WO 97/23478, WO 97/26246,  
 WO 97/30053, WO 97/44350, WO 98/02436, and U.S. Patent No. 5,532,359.

For an example of the role of a prenyl-protein transferase inhibitor on angiogenesis  
 see *European J. of Cancer*, Vol. 35, No. 9, pp.1394-1401 (1999).

“Angiogenesis inhibitors” refers to compounds that inhibit the  
 10 formation of new blood vessels, regardless of mechanism. Examples of angiogenesis  
 inhibitors include, but are not limited to, tyrosine kinase inhibitors, such as inhibitors  
 of the tyrosine kinase receptors Flt-1 (VEGFR1) and Flk-1/KDR (VEGFR2),  
 inhibitors of epidermal-derived, fibroblast-derived, or platelet derived growth factors,  
 MMP (matrix metalloprotease) inhibitors, integrin blockers, interferon- $\alpha$ , interleukin-  
 15 12, pentosan polysulfate, cyclooxygenase inhibitors, including nonsteroidal anti-  
 inflammatories (NSAIDs) like aspirin and ibuprofen as well as selective cyclooxy-  
 genase-2 inhibitors like celecoxib and rofecoxib (PNAS, Vol. 89, p. 7384 (1992);  
 JNCI, Vol. 69, p. 475 (1982); Arch. Ophthalmol., Vol. 108, p.573 (1990); Anat. Rec.,  
 Vol. 238, p. 68 (1994); FEBS Letters, Vol. 372, p. 83 (1995); Clin. Orthop. Vol. 313,  
 20 p. 76 (1995); J. Mol. Endocrinol., Vol. 16, p.107 (1996); Jpn. J. Pharmacol., Vol. 75,  
 p. 105 (1997); Cancer Res., Vol. 57, p. 1625 (1997); Cell, Vol. 93, p. 705 (1998);  
 Intl. J. Mol. Med., Vol. 2, p. 715 (1998); J. Biol. Chem., Vol. 274, p. 9116 (1999)),  
 steroidal anti-inflammatories (such as corticosteroids, mineralocorticoids,  
 dexamethasone, prednisone, prednisolone, methylpred, betamethasone),  
 25 carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl)-  
 fumagillol, thalidomide, angiostatin, troponin-1, angiotensin II antagonists (see  
 Fernandez et al., J. Lab. Clin. Med. 105:141-145 (1985)), and antibodies to VEGF  
 (see, Nature Biotechnology, Vol. 17, pp.963-968 (October 1999); Kim et al., Nature,  
 362, 841-844 (1993); WO 00/44777; and WO 00/61186).

30 Other therapeutic agents that modulate or inhibit angiogenesis and may  
 also be used in combination with the compounds of the instant invention include  
 agents that modulate or inhibit the coagulation and fibrinolysis systems (see review in  
*Clin. Chem. La. Med.* 38:679-692 (2000)). Examples of such agents that modulate or  
 inhibit the coagulation and fibrinolysis pathways include, but are not limited to,  
 35 heparin (see *Thromb. Haemost.* 80:10-23 (1998)), low molecular weight heparins and


carboxypeptidase U inhibitors (also known as inhibitors of active thrombin activatable fibrinolysis inhibitor [TAFIa]) (see *Thrombosis Res.* 101:329-354 (2001)). TAFIa inhibitors have been described in U.S. Ser. Nos. 60/310,927 (filed August 8, 2001) and 60/349,925 (filed January 18, 2002).

5 As described above, the combinations with NSAID's are directed to the use of NSAID's which are potent COX-2 inhibiting agents. For purposes of this specification an NSAID is potent if it possess an  $IC_{50}$  for the inhibition of COX-2 of 1 $\mu$ M or less as measured by cell or microsomal assays.


10 The invention also encompasses combinations with NSAID's which are selective COX-2 inhibitors. For purposes of this specification NSAID's which are selective inhibitors of COX-2 are defined as those which possess a specificity for inhibiting COX-2 over COX-1 of at least 100 fold as measured by the ratio of  $IC_{50}$  for COX-2 over  $IC_{50}$  for COX-1 evaluated by cell or microsomal assays. Such compounds include, but are not limited to those disclosed in U.S. Patent 5,474,995, 15 issued December 12, 1995, U.S. Patent 5,861,419, issued January 19, 1999, U.S. Patent 6,001,843, issued December 14, 1999, U.S. Patent 6,020,343, issued February 1, 2000, U.S. Patent 5,409,944, issued April 25, 1995, U.S. Patent 5,436,265, issued July 25, 1995, U.S. Patent 5,536,752, issued July 16, 1996, U.S. Patent 5,550,142, issued August 27, 1996, U.S. Patent 5,604,260, issued February 18, 1997, U.S. 20 5,698,584, issued December 16, 1997, U.S. Patent 5,710,140, issued January 20, 1998, WO 94/15932, published July 21, 1994, U.S. Patent 5,344,991, issued June 6, 1994, U.S. Patent 5,134,142, issued July 28, 1992, U.S. Patent 5,380,738, issued January 10, 1995, U.S. Patent 5,393,790, issued February 20, 1995, U.S. Patent 5,466,823, issued November 14, 1995, U.S. Patent 5,633,272, issued May 27, 1997, 25 and U.S. Patent 5,932,598, issued August 3, 1999, all of which are hereby incorporated by reference.

Inhibitors of COX-2 that are particularly useful in the instant method of treatment are:

30 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; and



5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine;






5

or a pharmaceutically acceptable salt thereof.

General and specific synthetic procedures for the preparation of the COX-2 inhibitor compounds described above are found in U.S. Patent No. 5,474,995, issued December 12, 1995, U.S. Patent No. 5,861,419, issued January 19, 1999, and U.S. Patent No. 6,001,843, issued December 14, 1999, all of which are herein incorporated by reference.

Compounds that have been described as specific inhibitors of COX-2 and are therefore useful in the present invention include, but are not limited to, the following:



5

or a pharmaceutically acceptable salt thereof.

Compounds which are described as specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: WO 94/15932, published July 21, 1994, U.S. Patent No. 5,344,991, issued June 6, 1994, U.S. Patent No. 5,134,142, issued July 28, 1992, U.S. Patent No. 5,380,738, issued January 10, 1995, U.S. Patent No. 5,393,790,

issued February 20, 1995, U.S. Patent No. 5,466,823, issued November 14, 1995, U.S. Patent No. 5,633,272, issued May 27, 1997, and U.S. Patent No. 5,932,598, issued August 3, 1999.

Compounds which are specific inhibitors of COX-2 and are therefore useful in the present invention, and methods of synthesis thereof, can be found in the following patents, pending applications and publications, which are herein incorporated by reference: U.S. Patent No. 5,474,995, issued December 12, 1995, U.S. Patent No. 5,861,419, issued January 19, 1999, U.S. Patent No. 6,001,843, issued December 14, 1999, U.S. Patent No. 6,020,343, issued February 1, 2000, U.S. Patent No. 5,409,944, issued April 25, 1995, U.S. Patent No. 5,436,265, issued July 25, 1995, U.S. Patent No. 5,536,752, issued July 16, 1996, U.S. Patent No. 5,550,142, issued August 27, 1996, U.S. Patent No. 5,604,260, issued February 18, 1997, U.S. Patent No. 5,698,584, issued December 16, 1997, and U.S. Patent No. 5,710,140, issued January 20, 1998.

Other examples of angiogenesis inhibitors include, but are not limited to, endostatin, ukrain, ranpirnase, IM862, 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline, 5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)phenyl]methyl]-1H-1,2,3-triazole-4-carboxamide, CM101, squalamine, combretastatin, RPI4610, NX31838, sulfated mannopentaose phosphate, 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolocarbonyl-imino[N-methyl-4,2-pyrrole]-carbonylimino]-bis-(1,3-naphthalene disulfonate), and 3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone (SU5416).

As used above, "integrin blockers" refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the  $\alpha_v\beta_3$  integrin, to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the  $\alpha_v\beta_5$  integrin, to compounds which antagonize, inhibit or counteract binding of a physiological ligand to both the  $\alpha_v\beta_3$  integrin and the  $\alpha_v\beta_5$  integrin, and to compounds which antagonize, inhibit or counteract the activity of the particular integrin(s) expressed on capillary endothelial cells. The term also refers to antagonists of the  $\alpha_v\beta_6$ ,  $\alpha_v\beta_8$ ,  $\alpha_1\beta_1$ ,  $\alpha_2\beta_1$ ,  $\alpha_5\beta_1$ ,  $\alpha_6\beta_1$  and  $\alpha_6\beta_4$  integrins. The term also refers to antagonists of any combination of  $\alpha_v\beta_3$ ,  $\alpha_v\beta_5$ ,  $\alpha_v\beta_6$ ,  $\alpha_v\beta_8$ ,  $\alpha_1\beta_1$ ,  $\alpha_2\beta_1$ ,  $\alpha_5\beta_1$ ,  $\alpha_6\beta_1$  and  $\alpha_6\beta_4$  integrins.

Some specific examples of tyrosine kinase inhibitors include N-(trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide, 3-[(2,4-dimethylpyrrol-

5-yl)methylidenyl)indolin-2-one, 17-(allylamino)-17-demethoxygeldanamycin, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxyl]quinazoline, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, BIBX1382, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-hydroxy-9-methyl-9,12-epoxy-  
 5 1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, SH268, genistein, STI571, CEP2563, 4-(3-chlorophenylamino)-5,6-dimethyl-7H-pyrrolo [2,3-d]pyrimidinemethane sulfonate, 4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, SU6668, STI571A, N-4-chlorophenyl-4-(4-pyridylmethyl)-1-phthalazinamine, and  
 10 EMD121974.

Combinations with compounds other than anti-cancer compounds are also encompassed to treat conditions other than cancer. For example, combinations of the instantly claimed compounds with PPAR- $\gamma$  (i.e., PPAR-gamma) agonists and PPAR- $\delta$  (i.e., PPAR-delta) agonists are useful in the treatment of diabetic  
 15 retinopathy. PPAR- $\gamma$  is the nuclear peroxisome proliferator-activated receptor  $\gamma$ . The expression of PPAR- $\gamma$  on endothelial cells and its involvement in angiogenesis in corneal and choroidal experimental systems has been reported in the literature (see *J. Cardiovasc. Pharmacol.* 1998; 31:909-913; *J. Biol. Chem.* 1999; 274:9116-9121; *Invest. Ophthalmol Vis. Sci.* 2000; 41:2309-2317). More recently, PPAR- $\gamma$  agonists  
 20 have been shown to inhibit the angiogenic response to VEGF in vitro; both troglitazone and rosiglitazone maleate inhibit the development of retinal neovascularization in mice. (*Arch. Ophthalmol.* 2001; 119:709-717). Examples of PPAR- $\gamma$  agonists and PPAR-  $\gamma/\alpha$  agonists include, but are not limited to, thiazolidinediones (such as DRF2725, CS-011, troglitazone, rosiglitazone, and  
 25 pioglitazone), fenofibrate, gemfibrozil, clofibrate, GW2570, SB219994, AR-H039242, JTT-501, MCC-555, GW2331, GW409544, NN2344, KRP297, NP0110, DRF4158, NN622, GI262570, PNU182716, DRF552926, 2-[(5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy]-2-methylpropionic acid (disclosed in USSN 09/782,856), and 2(R)-7-(3-(2-chloro-4-(4-fluorophenoxy) phenoxy)propoxy)-  
 30 2-ethylchromane-2-carboxylic acid (disclosed in USSN 60/235,708 and 60/244,697).

Another embodiment of the instant invention is the use of the presently disclosed compounds in combination with gene therapy for the treatment of cancer. For an overview of genetic strategies to treating cancer see Hall et al (*Am J Hum Genet* 61:785-789, 1997) and Kufe et al (*Cancer Medicine*, 5th Ed, pp 876-889, BC  
 35 Decker, Hamilton 2000). Gene therapy can be used to deliver any tumor suppressing

gene. Examples of such genes include, but are not limited to, p53, which can be delivered via recombinant virus-mediated gene transfer (see U.S. Patent No. 6,069,134, for example), a uPA/uPAR antagonist ("Adenovirus-Mediated Delivery of a uPA/uPAR Antagonist Suppresses Angiogenesis-Dependent Tumor Growth and Dissemination in Mice," Gene Therapy, August 1998; 5(8):1105-13), and interferon gamma (J Immunol 2000;164:217-222).

When a composition according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.

In one exemplary application, a suitable amount of an inhibitor of Akt/PKB is administered to a mammal undergoing treatment for cancer. Administration occurs in an amount of inhibitor of between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day. A particular therapeutic dosage that comprises the instant composition includes from about 0.01mg to about 1000mg of inhibitor of Akt/PKB. Preferably, the dosage comprises from about 1mg to about 1000mg of inhibitor of Akt/PKB.

All patents, publications and pending patent applications identified are hereby incorporated by reference.

Abbreviations used in the description of the chemistry and in the Examples that follow are:

25	DCE	dichloroethane
	DCM	dichloromethane
	DMF	dimethylformamide
	EtOH	ethanol
	n-Pr	n-propyl
30	PS-NMM	polystyrene N-methylmorpholine
	TFA	trifluoroacetic acid

The compounds of this invention may be prepared by employing reactions as shown in the following schemes, in addition to other standard manipula-



5 tions that are known in the literature or exemplified in the experimental procedures. The illustrative schemes below, therefore, are not limited by the compounds listed or by any particular substituents employed for illustrative purposes. Substituent numbering as shown in the schemes does not necessarily correlate to that used in the claims and often, for clarity, a single substituent is shown attached to the compound where multiple substituents are allowed under the definitions of Formula A hereinabove.




10 Reactions used to generate the compounds of this invention are prepared by employing reactions as shown in the Schemes I-III, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Substituents R and R<sup>a</sup>, as shown in the Scheme, represent the substituents R<sup>1</sup> and R<sup>2</sup>; however their point of attachment to the ring is illustrative only and is not meant to be limiting.

15 These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the alkylation reactions described in the Schemes.


#### SYNOPSIS OF SCHEME I-III:



20 The requisite intermediates are in some cases commercially available, or can be prepared according to literature procedures. As illustrated in Scheme I, a suitably substituted phenylacetylide may be reacted with copper iodide to form the corresponding copper acetylide I-1 (see for example, Sonogashira, K.; Toda, Y.; Hagihara, N. *Tetrahedron Lett.* **1975**, 4467). Intermediate I may then react with a  
25 suitably substituted electrophilic phenyl moiety to provide the asymmetrically substituted diphenyl acetylene I-2. Reaction with NBS followed by hydrolysis provides the substituted benzil I-3 (see for example, Yussybov, M.S.; Filimonov, V.D.; *Synthesis* **1991**, 2, 131). A variety of substituted and unsubstituted benzils may also be obtained commercially.

30 Scheme II illustrates the preparation of the compounds of the instant invention, starting with a suitably substituted bromomethylbenzil II-1. This intermediate can be reacted with a suitably substituted aryl- or heteroaryldiamine to provide intermediate II-2. The bromine of II-2 can then be converted to the amine, which can react with a suitable sulfonyl chloride to provide a compound of the instant  
35 invention II-5.

Reaction Scheme I

## Reaction Scheme II



Reaction Scheme II (continued)


5


EXAMPLES

Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limiting of the reasonable scope thereof.

10

## SCHEME 1





Step 1: 2-[4-Bromomethyl]phenyl-3-phenylquinoxaline 1-2

To a 20 mL vial was placed bromomethyl benzil (Toronto Research Chemicals, 1 g, 3.3 mmol), 1,2-diaminobenzene (356 mg, 3.3 mmol) and dry dichloroethane (8 mL). The vial was placed on a J-KEM heater/shaker block at 80 degrees. After 20 minutes, white needles crashed out of solution. The vial was then allowed to slowly cool to room temperature, filtered and washed with cold DCE to afford, after drying under high vacuum, compound 1-2 as white needles. Analytical LCMS (>98%, 376.2 [M+1]): single peak (214 nm) at 3.860 min (CH<sub>3</sub>CN/H<sub>2</sub>O/1%TFA, 4 min gradient). Material was used as in the next step.

Step 2: 1-[4-(3-Phenylquinoxalin-2-yl)phenyl]metanamine 1-4

To a 50 mL round-bottom flask, equipped with stir bar and septa, was placed 2-[4-bromomethyl]phenyl-3-phenylquinoxaline 1-2 (1.0 g, 2.7 mol), phthalimide (393 mg, 2.7 mmol), K<sub>2</sub>CO<sub>3</sub> (372 mg, 2.7 mol) and DMF (15 mL). The reaction was allowed to stir overnight at room temperature. In the morning, the reaction was quenched with water and extracted into EtOAc. The combined organics were washed with sat'd K<sub>2</sub>CO<sub>3</sub> and concentrated to afford a pale yellow solid 1-3. Analytical LCMS (>98%, 442.2[M+1]): single peak (214 nm) at 3.04 min (CH<sub>3</sub>CN/H<sub>2</sub>O/1%TFA, 4 min gradient). This material was then dissolved in EtOH

(15 mL) and hydrazine (325 uL, 3.3 mmol) was added. After 30 minutes at room temperature, the reaction was quenched with water, extracted into DCM, washed with sat'd  $K_2CO_3$  and concentrated to provide a foamy brown solid. The material was passed through an Accu-bond silica plug to provide compound 1-4 as a brown solid.


- 5 Analytical LCMS (>98%, 295.3[M+1]): single peak (214 nm) at 1.760 min ( $CH_3CN/H_2O/1\%TFA$ , 4 min gradient).  $^1H$  NMR (300 MHz,  $CDCl_3$ ):  $\delta$  8.17 (m, 2H), 7.72 (m, 2H), 7.55 (m, 4H), 7.34 (m, 5H), 3.89 (s, 2H), 1.72 (bs, 2H). HRMS calc'd for  $C_{21}H_{17}N_3(M+H)$ , 312.1495; found, 312.1491.

10 Step 3: N-[4-(3-Phenylquinoxalin-2-yl)benzyl]propane-1-sulfonamide 1-5

- To an 8 mL vial was placed 1-[4-(3-phenylquinoxalin-2-yl)phenyl]metanamine 1-4 (25 mg, 0.07 mmol), PS-NMM (106 mg, 0.21 mmol, 1.97 mmol/g), and dry DCM (5 mL). Then, propylsulfonyl chloride (15  $\mu$ L, 0.105 mmol) was added, and the vial placed on a GlasCol rotator overnight. In the morning, PS-trisamine resin (103 mg, 0.35 mmol, 3.38 mmol/g) was added to scavenge the excess sulfonyl chloride. After 3 hours, the vial was filtered, washed with DCM and concentrated. The crude material was then purified on an Agilent 1100 series Mass Guided HPLC purification system to afford compound 1-5 as a pale yellow solid.
- 15 Analytical LCMS(>98%, 419.5[M+H]): single peak (214 nm) at 3.42 min ( $CH_3CN/H_2O/1\%TFA$ , 4 min gradient).  $^1H$  NMR (300 MHz,  $DMSO-d_6$ ):  $\delta$  8.14 (m, 2H), 7.88 (m, 2H), 7.63 (t,  $J=3$  Hz, 1H), 7.46 (m, 4H), 7.34 (m, 5H), 4.14 (d,  $J=6.3$  Hz, 2H), 2.87 (t,  $J=6.9$  Hz, 2H), 1.62 (m, 2H), 0.90 (t,  $J=7.2$  Hz, 3H). HRMS calc'd for  $C_{24}H_{23}N_3O_2S(M+H)$ , 418.1584; found, 418.1581.
- 20

- 25 Compounds in Table 1 were synthesized as shown in Scheme 1, but substituting the appropriately substituted sulfonylchloride for propylsulfonyl chloride in the scheme.

Table 1



R	MS (M+1)	R	MS (M+1)
	452.5		530.6
	444.4		418.5
	458.5		526.7
	466.5		512.6
	458.4		503.6
	509.6		545.7
	531.4		
	502.6		



EXAMPLE 1Cloning of the human Akt isoforms and  $\Delta$ PH-Akt1

5 The pS2neo vector (deposited in the ATCC on April 3, 2001 as ATCC  
PTA-3253) was prepared as follows: The pRmHA3 vector (prepared as described in  
*Nucl. Acid Res.* 16:1043-1061 (1988)) was cut with BglII and a 2734 bp fragment was  
isolated. The pUCHsneo vector (prepared as described in *EMBO J.* 4:167-171 (1985))  
was also cut with BglII and a 4029 bp band was isolated. These two isolated  
10 fragments were ligated together to generate a vector termed pS2neo-1. This plasmid  
contains a polylinker between a metallothionine promoter and an alcohol  
dehydrogenase poly A addition site. It also has a neo resistance gene driven by a heat  
shock promoter. The pS2neo-1 vector was cut with Psp5II and BsiWI. Two  
complementary oligonucleotides were synthesized and then annealed  
(CTGCGGCCGC (SEQ.ID.NO.: 1) and GTACGCGGCCGCAG (SEQ.ID.NO.: 2)).  
15 The cut pS2neo-1 and the annealed oligonucleotides were ligated together to generate  
a second vector, pS2neo. Added in this conversion was a NotI site to aid in the  
linearization prior to transfection into S2 cells.

Human Akt1 gene was amplified by PCR (Clontech) out of a human  
spleen cDNA (Clontech) using the 5' primer:  
20 5' CGCGAATTCAGATCTACCASTEAGCGACGTGGCTATTGTG 3'  
(SEQ.ID.NO.: 3), and the 3' primer:  
5'CGCTCTAGAGGATCCTCAGGCCGTGCTGCTGGC3' (SEQ.ID.NO.: 4). The  
5' primer included an EcoRI and BglII site. The 3' primer included an XbaI and  
BamHI site for cloning purposes. The resultant PCR product was subcloned into  
25 pGEM3Z (Promega) as an EcoRI / Xba I fragment. For expression/purification  
purposes, a middle T tag was added to the 5' end of the full length Akt1 gene using  
the PCR primer: 5'GTACGATGCTGAACGATATCTTCG 3' (SEQ.ID.NO.: 5). The  
resulting PCR product encompassed a 5' KpnI site and a 3' BamHI site which were  
used to subclone the fragment in frame with a biotin tag containing insect cell  
30 expression vector, pS2neo.

For the expression of a pleckstrin homology domain PH) deleted ( $\Delta$ aa  
4-129, which includes deletion of a portion of the Akt1 hinge region) version of Akt1,  
PCR deletion mutagenesis was done using the full length Akt1 gene in the pS2neo  
vector as template. The PCR was carried out in 2 steps using overlapping internal  
35 primers

(5'GAATACATGCCGATGGAAAGCGACAGGGGCTGAAGAGATGGAGGTG 3'  
(SEQ.ID.NO.: 6), and

5'CCCCTCCATCTCTTCAGCCCCAGTCGCTTTCCATCGGCATG

TATTC 3' (SEQ.ID.NO.: 7)) which encompassed the deletion and 5' and 3' flanking

- 5 primers which encompassed the KpnI site and middle T tag on the 5' end. The final PCR product was digested with KpnI and SmaI and ligated into the pS2neo full length Akt1 KpnI / Sma I cut vector, effectively replacing the 5' end of the clone with the deleted version.

Human Akt3 gene was amplified by PCR of adult brain cDNA

- 10 (Clontech) using the amino terminal oligo primer:

5' GAATTCAGATCTACCATGAGCGATGTTACCATTGTG 3' (SEQ.ID.NO.: 8);

and the carboxy terminal oligo primer :

5' TCTAGATCTTATTCTCGTCCACTTGCAGAG 3' (SEQ.ID.NO.: 9).

These primers included a 5' EcoRI / BglII site and a 3' XbaI / BglII site for cloning

- 15 purposes. The resultant PCR product was cloned into the EcoRI and XbaI sites of pGEM4Z (Promega). For expression / purification purposes, a middle T tag was added to the 5' end of the full length Akt3 clone using the PCR primer: 5' GGTACCATGGAATACATGCCGATGGAAAGCGATGTTACCATTGTGAAG 3' (SEQ.ID.NO.: 10). The resultant PCR product encompassed a 5' KpnI site which  
20 allowed in frame cloning with the biotin tag containing insect cell expression vector, pS2neo.

Human Akt2 gene was amplified by PCR from human thymus cDNA

(Clontech) using the amino terminal oligo primer:

5' AAGCTTAGATCTACCATGAATGAGGTGTCTGTC 3' (SEQ.ID.NO.: 11); and

- 25 the carboxy terminal oligo primer:

5'GAATTCGGATCCTCACTCGCGGATGCTGGC 3' (SEQ.ID.NO.: 12). These

primers included a 5' HindIII / BglII site and a 3' EcoRI / BamHI site for cloning purposes. The resultant PCR product was subcloned into the HindIII / EcoRI sites of

- pGem3Z (Promega). For expression / purification purposes, a middle T tag was  
30 added to the 5' end of the full length Akt2 using the PCR primer: 5' GGTACCATGGAATACATGCCGATGGAAAATGAGGTGTCTGTCATCAAAG 3' (SEQ.ID.NO.: 13). The resultant PCR product was subcloned into the pS2neo vector as described above.

EXAMPLE 2Expression of human Akt isoforms and  $\Delta$ PH-Akt1

The DNA containing the cloned Akt1, Akt2, Akt3 and  $\Delta$ PH-Akt1 genes in the pS2neo expression vector was purified and used to transfect *Drosophila* S2 cells (ATCC) by the calcium phosphate method. Pools of antibiotic (G418, 500  $\mu$ g/ml) resistant cells were selected. Cells were expanded to a 1.0L volume ( $\sim 7.0 \times 10^6$  / ml), biotin and  $\text{CuSO}_4$  were added to a final concentration of 50  $\mu$ M and 50 mM respectively. Cells were grown for 72h at 27°C and harvested by centrifugation. The cell paste was frozen at -70°C until needed.

EXAMPLE 3Purification of human Akt isoforms and  $\Delta$ PH-Akt1

Cell paste from one liter of S2 cells, described in Example 2, was lysed by sonication with 50mls 1% CHAPS in buffer A: (50mM Tris pH 7.4, 1mM EDTA, 1mM EGTA, 0.2mM AEBSF, 10 $\mu$ g/ml benzamidine, 5 $\mu$ g/ml of leupeptin, aprotinin and pepstatin each, 10% glycerol and 1mM DTT). The soluble fraction was purified on a Protein G Sepharose fast flow (Pharmacia) column loaded with 9mg/ml anti-middle T monoclonal antibody and eluted with 75 $\mu$ M EYMPME (SEQ.ID.NO.: 14) peptide in buffer A containing 25% glycerol. Akt/PKB containing fractions were pooled and the protein purity evaluated by SDS-PAGE. The purified protein was quantitated using a standard Bradford protocol. Purified protein was flash frozen on liquid nitrogen and stored at -70°C.

Akt and Akt pleckstrin homology domain deletions purified from S2 cells required activation. Akt and Akt pleckstrin homology domain deletions were activated (Alessi et al. *Current Biology* 7:261-269) in a reaction containing 10 nM PDK1 (Upstate Biotechnology, Inc.), lipid vesicles (10  $\mu$ M phosphatidylinositol-3,4,5-trisphosphate – Metreya, Inc, 100  $\mu$ M phosphatidylcholine and 100  $\mu$ M phosphatidylserine – Avanti Polar lipids, Inc.) and activation buffer (50 mM Tris pH7.4, 1.0 mM DTT, 0.1 mM EGTA, 1.0  $\mu$ M Microcystin-LR, 0.1 mM ATP, 10 mM  $\text{MgCl}_2$ , 333  $\mu$ g/ml BSA and 0.1mM EDTA). The reaction was incubated at 22°C for 4 hours. Aliquots were flash frozen in liquid nitrogen.

EXAMPLE 4Kinase Assays

This procedure describes a kinase assay which measures phosphorylation of a biotinylated GSK3-derived peptide by human recombinant active Akt/PBK isoforms or Akt/PBK mutants. The <sup>33</sup>P-labeled biotinylated product can be captured and detected using Streptavidin coated Flashplates (NEN LifeSciences) or Streptavidin Membrane Filter Plates (Promega). Alternatively, a GSK3-derived peptide with 2 added lysine residues was used as the substrate and subsequently captured using Phosphocellulose Membrane Filter Plates (Polyfiltronics).

## Materials:

Active human Akt: The following active human Akt isoforms were utilized in the *in vitro* assays: active human Akt1 (obtained from Upstate Biotechnology, catalog no. 14-276, 15 µg/ 37 µl (6.76 µM)) or recombinant lipid activated Akt1 (prepared as described in Example 3); recombinant lipid activated Akt2 (prepared as described in Example 3); recombinant lipid activated Akt3 (prepared as described in Example 3); and recombinant lipid activated delta PH-Akt1 (prepared as described in Example 3).

Akt specific peptide substrate: GSK3α (S21) Peptide #3928, biotin-GGRARTSSFAEPG (SEQ.ID.NO.: 15), FW = 1517.8 (obtained from Macromolecular Resources) for Streptavidin Flashplate or Streptavidin Filter Plate detection.

GSK3α (S21) Peptide #G80613, KKGGRARTSSFAEPG (SEQ.ID.NO.: 14), FW = 1547.8 (obtained from Research Genetics) for Phosphocellulose filter plate detection.

## Standard Assay Solutions:

A. 10X Assay Buffer: 500 mM HEPES, pH 7.5  
1% PEG  
1 mM EDTA  
1 mM EGTA

20 mM  $\beta$ -Glycerol phosphate

- 5 B. Active Akt (500 nM): Diluent (1X Assay buffer, 10% glycerol, 0.1%  $\beta$ -mercaptoethanol, 1.0  $\mu$ M microcystin LR and 1.0 mM EDTA) was added to a vial containing 37  $\mu$ l of active Akt isoform (6.76  $\mu$ M). Aliquots were flash frozen in liquid  $N_2$  and stored at  $-70^\circ\text{C}$ .
- 10 C. 1 mM Akt specific peptide substrate in 50 mM Tris pH 7.5, 1 mM DTT.
- D. 100 mM DTT in di  $H_2O$ .
- 15 E. 100X Protease Inhibitor Cocktail (PIC): 1 mg/ml benzamidine, 0.5 mg/ml pepstatin, 0.5 mg/ml leupeptin, 0.5 mg/ml aprotinin.
- F. 3 mM ATP, 200 mM  $MgCl_2$  in  $H_2O$ , pH 7.9.
- 20 G. 50% (v/v) Glycerol.
- H. 1% (wt/v) BSA (10 mg/ml) in di $H_2O$ , 0.02% (w/v)  $NaN_3$ .
- I. 125 mM EDTA.
- 25 J. 0.75% (wt/v) Phosphoric Acid.
- K. 2.5 M Potassium Chloride.
- 30 L. Tris Buffered Saline (TBS), 25 mM Tris, 0.15 M Sodium Chloride, pH 7.2 (BupH Tris Buffered Saline Pack, Pierce catalog no. 28376).

### Procedure for Streptavidin Flash Plate Assay:

#### Step 1:

5 A 1  $\mu$ l solution of the test compound in 100% DMSO was added to 20  $\mu$ l of 2X  
substrate solution (20  $\mu$ M GSK3 Peptide, 300  $\mu$ M ATP, 20 mM  $MgCl_2$ , 20  $\mu$ Ci / ml  
[ $\gamma^{33}P$ ] ATP, 1X Assay Buffer, 5% glycerol, 1 mM DTT, 1X PIC, 0.1% BSA and 100  
mM KCl). Phosphorylation reactions were initiated by adding 19  $\mu$ l of 2X Enzyme  
10 solution (6.4 nM active Akt/PKB, 1X Assay Buffer, 5% glycerol, 1 mM DTT, 1X  
PIC and 0.1% BSA). The reactions were then incubated at room temperature for 45  
minutes.

#### Step 2:

15 The reaction was stopped by adding 170  $\mu$ l of 125 mM EDTA. 200  $\mu$ l of stopped  
reaction was transferred to a Streptavidin Flashplate<sup>®</sup> PLUS (NEN Life Sciences,  
catalog no. SMP103). The plate was incubated for  $\geq 10$  minutes at room temperature  
on a plate shaker. The contents of each well was aspirated, and the wells rinsed 2  
times with 200  $\mu$ l TBS per well. The wells were then washed 3 times for 5 minutes  
with 200  $\mu$ l TBS per well with the plates incubated at room temperature on a platform  
shaker during wash steps.

20 The plates were covered with sealing tape and counted using the  
Packard TopCount with the appropriate settings for counting [ $^{33}P$ ] in Flashplates.

### Procedure for Streptavidin Filter Plate Assay:

#### Step 1:

25 The enzymatic reactions as described in Step 1 of the Streptavidin Flash Plate Assay  
above were performed.

#### Step 2:

30 The reaction was stopped by adding 20  $\mu$ l of 7.5M Guanidine Hydrochloride. 50  $\mu$ l of  
the stopped reaction was transferred to the Streptavidin filter plate (SAM<sup>2™</sup> Biotin  
Capture Plate, Promega, catalog no. V7542) and the reaction was incubated on the  
filter for 1-2 minutes before applying vacuum.

The plate was then washed using a vacuum manifold as follows: 1) 4 x 200 µl/well of 2M NaCl; 2) 6 x 200 µl/well of 2M NaCl with 1% H<sub>3</sub>PO<sub>4</sub>; 3) 2 x 200 µl/well of diH<sub>2</sub>O; and 4) 2 x 100 µl/well of 95% Ethanol. The membranes were then allowed to air dry completely before adding scintillant.

5

The bottom of the plate was sealed with white backing tape, 30 µl/well of Microscint 20 (Packard Instruments, catalog no. 6013621) was added. The top of the plate was sealed with clear sealing tape, and the plate then counted using the Packard TopCount with the appropriate settings for [<sup>33</sup>P] with liquid scintillant.

10

#### Procedure for Phosphocellulose Filter Plate Assay:

##### Step 1:

The enzymatic reactions were performed as described in Step 1 of the Streptavidin Flash Plate Assay (above) utilizing KKGGRARTSSFAEPG (SEQ.ID.NO.: 16) as the substrate in place of biotin-GGRARTSSFAEPG.

15

##### Step 2:

The reaction was stopped by adding 20 µl of 0.75% H<sub>3</sub>PO<sub>4</sub>. 50 µl of stopped reaction was transferred to the filter plate (UNIFILTER™, Whatman P81 Strong Cation Exchanger, White Polystyrene 96 Well Plates, Polyfiltronics, catalog no. 7700-3312) and the reaction incubated on the filter for 1-2 minutes before applying vacuum.

20

The plate was then washed using a vacuum manifold as follows: 1) 9 x 200 µl/well of 0.75% H<sub>3</sub>PO<sub>4</sub>; and 2) 2 x 200 µl/well of diH<sub>2</sub>O. The bottom of the plate was sealed with white backing tape, then 30 µl/well of Microscint 20 was added. The top of the plate was sealed with clear sealing tape, and the plate counted using the Packard TopCount with the appropriate settings for [<sup>33</sup>P] and liquid scintillant.

25

#### 30 PKA Assay

Each individual PKA assay consists of the following components:

- 1) 10  $\mu$ l 5X PKA assay buffer (200 mM Tris pH7.5, 100 mM  $MgCl_2$ , 5mM 2-mercaptoethanol, 0.5 mM EDTA)
- 2) 10  $\mu$ l of a 50  $\mu$ M stock of Kemptide (Sigma) diluted into water
- 3) 10  $\mu$ l  $^{33}P$ -ATP (prepared by diluting 1.0  $\mu$ l  $^{33}P$ -ATP [10 mCi/ml] into 200  $\mu$ l of a 50  $\mu$ M stock of unlabeled ATP)
- 4) 10  $\mu$ l appropriate solvent control dilution or inhibitor dilution
- 5) 10  $\mu$ l of a 70 nM stock of PKA catalytic subunit (UBI catalog # 14-114) diluted in 0.5 mg/ml BSA

The final assay concentrations were 40 mM Tris pH 7.5, 20 mM  $MgCl_2$ , 1 mM 2-mercaptoethanol, 0.1 mM EDTA, 10  $\mu$ M Kemptide, 10  $\mu$ M  $^{33}P$ -ATP, 14 nM PKA and 0.1 mg/ml BSA.

Assays were assembled in 96 deep-well assay plates. Components #3 and #4 were premixed and in a separate tube, a mixture containing equal volumes of components #1, #2, and #5 was prepared. The assay reaction was initiated by adding 30  $\mu$ l of the components #1, #2, and #5 mixture to wells containing  $^{33}P$ -ATP and inhibitor. The liquid in the assay wells was mixed and the assay reactions incubated for 20 minutes at room temperature. The reactions were stopped by adding 50  $\mu$ l 100 mM EDTA and 100 mM sodium pyrophosphate and mixing.

The enzyme reaction product (phosphorylated Kemptide) was quantitated using p81 phosphocellulose 96 well filter plates (Millipore). Each well of a p81 filter plate was filled with 75 mM phosphoric acid. The wells were aspirated and 170  $\mu$ l of 75 mM phosphoric acid was added to each well. A 30-40  $\mu$ l aliquot from each stopped PKA reaction was added to corresponding wells on the filter plate containing the phosphoric acid. The peptide was trapped on the filter following the application of a vacuum. The filters were washed 5X by filling wells with 75 mM phosphoric acid followed by aspiration. After the final wash, the filters were allowed to air dry. 30  $\mu$ l scintillation fluid was added to each well and the filters counted on a TopCount (Packard).



PKC Assay

Each PKC assay consists of the following components:

- 5    1)            5  $\mu$ l 10X PKC co-activation buffer (2.5 mM EGTA, 4mM CaCl<sub>2</sub>)
- 2)            10  $\mu$ l 5X PKC activation buffer (1.6 mg/ml phosphatidylserine, 0.16  
                     mg/ml diacylglycerol, 100 mM Tris pH 7.5, 50 mM MgCl, 5 mM 2-  
                     mercaptoethanol)
- 10    3)            5  $\mu$ l <sup>33</sup>P-ATP (prepared by diluting 1.0  $\mu$ l <sup>33</sup>P-ATP [10 mCi/ml] into  
                     100 $\mu$ l of a 100  $\mu$ M stock of unlabeled ATP)
- 4)            10  $\mu$ l of a 350  $\mu$ g/ml stock of myelin basic protein (MBP, UBI) diluted  
15                in water
- 5)            10  $\mu$ l appropriate solvent control or inhibitor dilution
- 20    6)            10 $\mu$ l of a 50ng/ml stock of PKC (mix of isoforms from UBI catalog #  
                     14-115) diluted into 0.5 mg/ml BSA

Final assay concentrations were as follows: 0.25 mM EGTA, 0.4 mM CaCl, 20 mM Tris pH 7.5, 10 mM MgCl, 1 mM 2-mercaptoethanol, 0.32 mg/ml phosphatidylserine, 0.032 mg/ml diacylglycerol, 10  $\mu$ M <sup>33</sup>P-ATP, 70  $\mu$ g/ml MBP, 10 ng/ml PKC, 0.1  
25 mg/ml BSA.

Assays are performed using 96 deep well assay plates. In each assay well 10  $\mu$ l of solvent control or appropriate inhibitor dilution with 5  $\mu$ l <sup>33</sup>P-ATP (components #5 and #3) were premixed. In a separate tube, a mixture containing equal volumes of components #1, #2, #4, and #6 was prepared. The assay reaction  
30 was initiated by adding 35  $\mu$ l of the components #1, #2, #4, and #6 mixture to wells containing <sup>33</sup>P-ATP and inhibitor. The liquid in the assay wells was thoroughly mixed and the assay reactions incubated for 20 minutes at room temperature. The reactions were stopped by adding 100 mM EDTA (50  $\mu$ l) and 100 mM sodium pyrophosphate (50  $\mu$ l) and mixing. Phosphorylated MBP was collected on PVDF membranes in 96  
35 well filter plates and quantitated by scintillation counting.

Compounds of the instant invention described in Scheme 1 and Table 1 above were tested in the assay described above and were found to have  $IC_{50}$  of  $\leq 50 \mu M$  against one or more of Akt1, Akt2 and Akt3.

5

### EXAMPLE 5

#### Cell based Assays to Determine Inhibition of Akt/PKB

Cells (for example LnCaP or a PTEN<sup>+/+</sup> tumor cell line with activated Akt/PKB) were plated in 100mm dishes. When the cells were approximately 70 to 80% confluent, the cells were refed with 5mls of fresh media and the test compound added in solution. Controls included untreated cells, vehicle treated cells and cells treated with either LY294002 (Sigma) or wortmanin (Sigma) at 20  $\mu M$  or 200 nM, respectively. The cells were incubated for 2 hrs, and the media removed. The cells were washed with PBS, scraped and transferred to a centrifuge tube. They were pelleted and washed again with PBS. Finally, the cell pellet was resuspended in lysis buffer (20 mM Tris pH8, 140 mM NaCl, 2 mM EDTA, 1% Triton, 1 mM Na Pyrophosphate, 10 mM  $\beta$ -Glycerol Phosphate, 10 mM NaF, 0.5 mM  $NaVO_4$ , 1  $\mu M$  Microsystine, and 1x Protease Inhibitor Cocktail), placed on ice for 15 minutes and gently vortexed to lyse the cells. The lysate was spun in a Beckman tabletop ultra centrifuge at 100,000 x g at 4°C for 20min. The supernatant protein was quantitated by a standard Bradford protocol (BioRad) and stored at -70° C until needed.

Proteins were immunoprecipitated (IP) from cleared lysates as follows: For Akt1/PKB $\alpha$ , lysates are mixed with Santa Cruz sc-7126 (D-17) in NETN (100mM NaCl, 20mM Tris pH 8.0, 1mM EDTA, 0.5% NP-40) and Protein A/G Agarose (Santa Cruz sc-2003) was added. For Akt2/PKB $\beta$ , lysates were mixed in NETN with anti-Akt-2 agarose (Upstate Biotechnology #16-174) and for Akt3/PKB $\gamma$ , lysates were mixed in NETN with anti-Akt-3 agarose (Upstate Biotechnology #16-175). The IPs were incubated overnight at 4° C, washed and separated by SDS-PAGE.

Western blots were used to analyze total Akt, pThr308 Akt, pSer473 Akt, and downstream targets of Akt using specific antibodies (Cell Signaling Technology): Anti-Total Akt (cat. no. 9272), Anti-Phospho Akt Serine 473 (cat. no. 9271), and Anti-Phospho Akt Threonine 308 (cat. no. 9275). After incubating with the appropriate primary antibody diluted in PBS + 0.5% non-fat dry milk (NFDm) at

4 °C overnight, blots were washed, incubated with Horseradish peroxidase (HRP)-tagged secondary antibody in PBS + 0.5% NFDm for 1 hour at room temperature. Proteins were detected with ECL Reagents (Amersham/Pharmacia Biotech RPN2134).

5

#### EXAMPLE 6

##### Heregulin Stimulated Akt Activation

10 MCF7 cells (a human breast cancer line that is PTEN<sup>+/+</sup>) were plated at 1x10<sup>6</sup> cells per 100mm plate. When the cells were 70 – 80% confluent, they were refed with 5 ml of serum free media and incubated overnight. The following morning, compound was added and the cells were incubated for 1 – 2 hrs, heregulin was added (to induce the activation of Akt) for 30 minutes and the cells were  
15 analyzed as described above.

#### EXAMPLE 7


##### Inhibition Of Tumor Growth

20 In vivo efficacy of an inhibitor of the growth of cancer cells may be confirmed by several protocols well known in the art.

Human tumor cell lines which exhibit a deregulation of the PI3K pathway (such as LnCaP, PC3, C33a, OVCAR-3, MDA-MB-468 or the like) are injected subcutaneously into the left flank of 8-12 week old female nude mice  
25 (Harlan) on day 0. The mice are randomly assigned to a vehicle, compound or combination treatment group. Daily subcutaneous administration begins on day 1 and continues for the duration of the experiment. Alternatively, the inhibitor test compound may be administered by a continuous infusion pump. Compound, compound combination or vehicle is delivered in a total volume of 0.1 ml. Tumors  
30 are excised and weighed when all of the vehicle-treated animals exhibited lesions of 0.5 - 1.0 cm in diameter, typically 4 to 5.5 weeks after the cells were injected. The average weight of the tumors in each treatment group for each cell line is calculated.

WHAT IS CLAIMED IS:

1. A compound of the formula A:



wherein:

- a is 0 or 1;  
 10 b is 0 or 1;  
 m is 0, 1 or 2;  
 n is 0, 1, 2 or 3;  
 p is 0, 1 or 2;  
 r is 0 or 1;  
 15 s is 0 or 1;  
 t is 2, 3, 4, 5 or 6;
- u, v, w and x are independently selected from: CH and N;
- 20 y and z are independently selected from: CH and N, provided that at least one of y and z is N;

R<sup>1</sup> is independently selected from:

- 25 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,  
 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,  
 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,  
 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,

- 5)  $(C=O)_aO_b$  heterocyclyl,  
 6)  $(C=O)_aO_bC_3-C_8$  cycloalkyl,  
 7)  $CO_2H$ ,  
 8) halo,  
 9) CN,  
 10) OH,  
 11)  $O_bC_1-C_6$  perfluoroalkyl,  
 12)  $O_a(C=O)_bNR^7R^8$ ,  
 13)  $NR^c(C=O)NR^7R^8$ ,  
 14)  $S(O)_mR^a$ ,  
 15)  $S(O)_2NR^7R^8$ ,  
 16)  $NR^cS(O)_mR^a$ ,  
 17) oxo,  
 18) CHO,  
 19)  $NO_2$ ,  
 20)  $NR^c(C=O)O_bR^a$ ,  
 21)  $O(C=O)O_bC_1-C_{10}$  alkyl,  
 22)  $O(C=O)O_bC_3-C_8$  cycloalkyl,  
 23)  $O(C=O)O_b$ aryl, and  
 24)  $O(C=O)O_b$ -heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from  $R^Z$ ;

$R^2$  is independently selected from:

- 1)  $(C=O)_aO_bC_1-C_{10}$  alkyl,  
 2)  $(C=O)_aO_b$ aryl,  
 3)  $C_2-C_{10}$  alkenyl,  
 4)  $C_2-C_{10}$  alkynyl,  
 5)  $(C=O)_aO_b$  heterocyclyl,  
 6)  $(C=O)_aO_bC_3-C_8$  cycloalkyl,  
 7)  $CO_2H$ ,  
 8) halo,  
 9) CN,  
 10) OH,

- 208040" 94802E09
- 11)  $O_bC_1-C_6$  perfluoroalkyl,
  - 12)  $O_a(C=O)_bNR^7R^8$ ,
  - 13)  $NR^c(C=O)NR^7R^8$ ,
  - 14)  $S(O)_mR^a$ ,
  - 5 15)  $S(O)_2NR^7R^8$ ,
  - 16)  $NR^cS(O)_mR^a$ ,
  - 17)  $CHO$ ,
  - 18)  $NO_2$ ,
  - 19)  $NR^c(C=O)O_bR^a$ ,
  - 10 20)  $O(C=O)O_bC_1-C_{10}$  alkyl,
  - 21)  $O(C=O)O_bC_3-C_8$  cycloalkyl,
  - 22)  $O(C=O)O_b$ aryl, and
  - 23)  $O(C=O)O_b$ -heterocycle,

15 said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from  $R^Z$ ;

$R^3$  and  $R^4$  are independently selected from: H,  $C_1-C_6$ -alkyl and  $C_1-C_6$ -perfluoroalkyl, or

- 20  $R^3$  and  $R^4$  are combined to form  $-(CH_2)_t-$  wherein one of the carbon atoms is optionally replaced by a moiety selected from O,  $S(O)_m$ ,  $-N(R^b)C(O)-$ , and  $-N(COR^a)-$ ;

$R^5$  is independently selected from:

- 25 1) H,
- 2)  $(C=O)O_bC_1-C_{10}$  alkyl,
- 3)  $(C=O)O_bC_3-C_8$  cycloalkyl,
- 4)  $(C=O)O_b$ aryl,
- 5)  $(C=O)O_b$ heterocyclyl,
- 30 6)  $C_1-C_{10}$  alkyl,
- 7) aryl,
- 8)  $C_2-C_{10}$  alkenyl,
- 9)  $C_2-C_{10}$  alkynyl,
- 10) heterocyclyl,

- 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 12) SO<sub>2</sub>R<sup>a</sup>, and
- 13) (C=O)NR<sup>b</sup><sub>2</sub>,

5 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>6</sup> is NR<sup>7</sup>R<sup>8</sup>, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, noboranyl, aryl, 2,2,2-trifluoroethyl, benzyl or heterocyclyl, said alkyl, cycloalkyl, noboranyl, aryl, heterocyclyl and benzyl is optionally substituted with one or more substituents  
10 selected from R<sup>Z</sup>;

R<sup>7</sup> and R<sup>8</sup> are independently selected from:

- 1) H,
- 2) (C=O)O<sup>b</sup>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 15 3) (C=O)O<sup>b</sup>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 4) (C=O)O<sup>b</sup>aryl,
- 5) (C=O)O<sup>b</sup>heterocyclyl,
- 6) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 7) aryl,
- 20 8) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 10) heterocyclyl,
- 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 12) SO<sub>2</sub>R<sup>a</sup>, and
- 25 13) (C=O)NR<sup>b</sup><sub>2</sub>,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

R<sup>7</sup> and R<sup>8</sup> can be taken together with the nitrogen to which they are attached to form  
30 a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>Z</sup> is selected from:

- 1) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,
- 2) O<sub>r</sub>(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkyl,
- 3) (C<sub>0</sub>-C<sub>6</sub>)alkylene-S(O)<sub>m</sub>R<sup>a</sup>,
- 4) oxo,
- 5) OH,
- 6) halo,
- 7) CN,
- 8) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkenyl,
- 9) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkynyl,
- 10) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
- 11) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-aryl,
- 12) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-heterocyclyl,
- 13) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-N(R<sup>b</sup>)<sub>2</sub>,
- 14) C(O)R<sup>a</sup>,
- 15) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>R<sup>a</sup>,
- 16) C(O)H,
- 17) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>H,
- 21) C(O)N(R<sup>b</sup>)<sub>2</sub>,
- 20) 22) S(O)<sub>m</sub>R<sup>a</sup>,
- 23) S(O)<sub>2</sub>N(R<sup>b</sup>)<sub>2</sub>
- 21) NRC(C=O)O<sub>b</sub>R<sup>a</sup>,
- 22) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 23) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 25) 24) O(C=O)O<sub>b</sub>aryl, and
- 25) O(C=O)O<sub>b</sub>-heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R<sup>b</sup>, OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen, CO<sub>2</sub>H, CN, O(C=O)C<sub>1</sub>-C<sub>6</sub> alkyl, oxo, and N(R<sup>b</sup>)<sub>2</sub>;

R<sup>a</sup> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, substituted or unsubstituted aryl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and



$R^b$  is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)OC<sub>1</sub>-C<sub>6</sub> alkyl, (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl or S(O)<sub>2</sub>R<sup>a</sup>;


5  $R^c$  is selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) aryl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 10 5) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 6) heterocyclyl,
- 7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 8) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

15 said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>z</sup>, or

or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. The compound according to Claim 1 of the formula B:



wherein:

- 25 n is 0, 1, 2 or 3;  
p is 0, 1 or 2;  
r is 0 or 1;

s is 0 or 1;

u, v, w and x are independently selected from: CH and N, provided that only one of u, v, w and x may be N;

5

R<sup>1</sup> is independently selected from:

- 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 2) (C=O)<sub>a</sub>O<sub>b</sub>aryl,
- 3) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 10 4) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 5) (C=O)<sub>a</sub>O<sub>b</sub> heterocyclyl,
- 6) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 7) CO<sub>2</sub>H,
- 8) halo,
- 15 9) CN,
- 10) OH,
- 11) O<sub>b</sub>C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,
- 12) O<sub>a</sub>(C=O)<sub>b</sub>NR<sup>7</sup>R<sup>8</sup>,
- 13) NR<sup>c</sup>(C=O)NR<sup>7</sup>R<sup>8</sup>,
- 20 14) S(O)<sub>m</sub>R<sup>a</sup>,
- 15) S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>,
- 16) NR<sup>c</sup>S(O)<sub>m</sub>R<sup>a</sup>,
- 17) oxo,
- 18) CHO,
- 25 19) NO<sub>2</sub>,
- 20) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,
- 21) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 22) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 23) O(C=O)O<sub>b</sub>aryl, and
- 30 24) O(C=O)O<sub>b</sub>-heterocycle,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>2</sup> is independently selected from:

- 35 1) (C=O)<sub>a</sub>O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,

- 2080412 " 94804E09
- 2)  $(\text{C}=\text{O})_a\text{O}_b\text{aryl}$ ,
  - 3)  $\text{C}_2\text{-C}_{10}$  alkenyl,
  - 4)  $\text{C}_2\text{-C}_{10}$  alkynyl,
  - 5)  $(\text{C}=\text{O})_a\text{O}_b$  heterocyclyl,
  - 5 6)  $(\text{C}=\text{O})_a\text{O}_b\text{C}_3\text{-C}_8$  cycloalkyl,
  - 7)  $\text{CO}_2\text{H}$ ,
  - 8) halo,
  - 9)  $\text{CN}$ ,
  - 10)  $\text{OH}$ ,
  - 10 11)  $\text{O}_b\text{C}_1\text{-C}_6$  perfluoroalkyl,
  - 12)  $\text{O}_a(\text{C}=\text{O})_b\text{NR}^7\text{R}^8$ ,
  - 13)  $\text{NR}^c(\text{C}=\text{O})\text{NR}^7\text{R}^8$ ,
  - 14)  $\text{S}(\text{O})_m\text{R}^a$ ,
  - 15)  $\text{S}(\text{O})_2\text{NR}^7\text{R}^8$ ,
  - 15 16)  $\text{NR}^c\text{S}(\text{O})_m\text{R}^a$ ,
  - 17)  $\text{CHO}$ ,
  - 18)  $\text{NO}_2$ ,
  - 19)  $\text{NR}^c(\text{C}=\text{O})\text{O}_b\text{R}^a$ ,
  - 20)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$  alkyl,
  - 20 21)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$  cycloalkyl,
  - 22)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{aryl}$ , and
  - 23)  $\text{O}(\text{C}=\text{O})\text{O}_b\text{-heterocycle}$ ,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from  $\text{R}^Z$ ;

25

$\text{R}^5$  is independently selected from:

- 1)  $\text{H}$ ,
- 2)  $(\text{C}=\text{O})\text{O}_b\text{C}_1\text{-C}_{10}$  alkyl,
- 3)  $(\text{C}=\text{O})\text{O}_b\text{C}_3\text{-C}_8$  cycloalkyl,
- 30 4)  $(\text{C}=\text{O})\text{O}_b\text{aryl}$ ,
- 5)  $(\text{C}=\text{O})\text{O}_b\text{heterocyclyl}$ ,
- 6)  $\text{C}_1\text{-C}_{10}$  alkyl,
- 7) aryl,
- 8)  $\text{C}_2\text{-C}_{10}$  alkenyl,

- 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,  
 10) heterocyclyl,  
 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 12) SO<sub>2</sub>R<sup>a</sup>, and  
 5 13) (C=O)NR<sup>b</sup><sub>2</sub>,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>;

- R<sup>6</sup> is NR<sup>7</sup>R<sup>8</sup>, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, noboranyl,  
 10 aryl, 2,2,2-trifluoroethyl, benzyl or heterocyclyl, said alkyl, cycloalkyl, noboranyl, aryl, heterocyclyl and benzyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>7</sup> and R<sup>8</sup> are independently selected from:

- 15 1) H,  
 2) (C=O)O<sup>b</sup>C<sub>1</sub>-C<sub>10</sub> alkyl,  
 3) (C=O)O<sup>b</sup>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 4) (C=O)O<sup>b</sup>aryl,  
 5) (C=O)O<sup>b</sup>heterocyclyl,  
 20 6) C<sub>1</sub>-C<sub>10</sub> alkyl,  
 7) aryl,  
 8) C<sub>2</sub>-C<sub>10</sub> alkenyl,  
 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,  
 10) heterocyclyl,  
 25 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 12) SO<sub>2</sub>R<sup>a</sup>, and  
 13) (C=O)NR<sup>b</sup><sub>2</sub>,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

- 30 R<sup>7</sup> and R<sup>8</sup> can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected

from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>Z</sup> is selected from:

- 5           1) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,
- 2) O<sub>r</sub>(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkyl,
- 3) (C<sub>0</sub>-C<sub>6</sub>)alkylene-S(O)<sub>m</sub>R<sup>a</sup>,
- 4) oxo,
- 5) OH,
- 10          6) halo,
- 7) CN,
- 8) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkenyl,
- 9) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkynyl,
- 10) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,
- 15          11) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-aryl,
- 12) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-heterocyclyl,
- 13) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-N(R<sup>b</sup>)<sub>2</sub>,
- 14) C(O)R<sup>a</sup>,
- 15) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>R<sup>a</sup>,
- 20          16) C(O)H,
- 17) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>H,
- 18) C(O)N(R<sup>b</sup>)<sub>2</sub>,
- 19) S(O)<sub>m</sub>R<sup>a</sup>,
- 20) S(O)<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>
- 25          21) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,
- 22) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 23) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 24) O(C=O)O<sub>b</sub>aryl, and
- 25) O(C=O)O<sub>b</sub>-heterocycle,
- 30          said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from R<sup>b</sup>, OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen, CO<sub>2</sub>H, CN, O(C=O)C<sub>1</sub>-C<sub>6</sub> alkyl, oxo, and N(R<sup>b</sup>)<sub>2</sub>;

$R^a$  is (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, substituted or unsubstituted aryl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, 2,2,2-trifluoroethyl, or substituted or unsubstituted heterocyclyl; and

- 5  $R^b$  is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)OC<sub>1</sub>-C<sub>6</sub> alkyl, (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl or S(O)<sub>2</sub>R<sup>a</sup>;


$R^c$  is selected from:

- 10           1) H,  
              2) C<sub>1</sub>-C<sub>10</sub> alkyl,  
              3) aryl,  
              4) C<sub>2</sub>-C<sub>10</sub> alkenyl,  
              5) C<sub>2</sub>-C<sub>10</sub> alkynyl,  
15           6) heterocyclyl,  
              7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
              8) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>z</sup>, or

20 or a pharmaceutically acceptable salt or a stereoisomer thereof.

3. The compound according to Claim 2 of the formula B:



wherein:

n is 0, 1, 2 or 3;

p is 0, 1 or 2;

r is 0 or 1;

s is 0 or 1;

5

u, v, w and x are independently selected from: CH and N, provided that only one of u, v, w and x may be N;

R<sup>1</sup> is independently selected from:

- |    |     |  |
|----|-----|--|
| 10 | 1)  | (C=O) <sub>a</sub> O <sub>b</sub> C <sub>1</sub> -C <sub>10</sub> alkyl,     |
|    | 2)  | (C=O) <sub>a</sub> O <sub>b</sub> aryl,                                      |
|    | 3)  | C <sub>2</sub> -C <sub>10</sub> alkenyl,                                     |
|    | 4)  | C <sub>2</sub> -C <sub>10</sub> alkynyl,                                     |
|    | 5)  | (C=O) <sub>a</sub> O <sub>b</sub> heterocyclyl,                              |
| 15 | 6)  | (C=O) <sub>a</sub> O <sub>b</sub> C <sub>3</sub> -C <sub>8</sub> cycloalkyl, |
|    | 7)  | CO <sub>2</sub> H,   |
|    | 8)  | halo,  |
|    | 9)  | CN,  |
|    | 10) | OH,  |
| 20 | 11) | O <sub>b</sub> C <sub>1</sub> -C <sub>6</sub> perfluoroalkyl,                |
|    | 12) | O <sub>a</sub> (C=O) <sub>b</sub> NR <sup>7</sup> R <sup>8</sup> ,           |
|    | 13) | NR <sup>c</sup> (C=O)NR <sup>7</sup> R <sup>8</sup> ,                        |
|    | 14) | S(O) <sub>m</sub> R <sup>a</sup> ,   |
|    | 15) | S(O) <sub>2</sub> NR <sup>7</sup> R <sup>8</sup> ,                           |
| 25 | 16) | NR <sup>c</sup> S(O) <sub>m</sub> R <sup>a</sup> ,                           |
|    | 17) | oxo,   |
|    | 18) | CHO,   |
|    | 19) | NO <sub>2</sub> ,  |
|    | 20) | NR <sup>c</sup> (C=O)O <sub>b</sub> R <sup>a</sup> ,                         |
| 30 | 21) | O(C=O)O <sub>b</sub> C <sub>1</sub> -C <sub>10</sub> alkyl,                  |
|    | 22) | O(C=O)O <sub>b</sub> C <sub>3</sub> -C <sub>8</sub> cycloalkyl,              |
|    | 23) | O(C=O)O <sub>b</sub> aryl, and   |
|    | 24) | O(C=O)O <sub>b</sub> -heterocycle,   |

35 said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R<sup>Z</sup>;

R<sup>2</sup> is independently selected from:

- 1) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 2) aryl,
- 3) heterocyclyl,
- 5 4) CO<sub>2</sub>H,
- 5) halo,
- 6) CN,
- 7) OH,
- 8) S(O)<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>,

- 10 said alkyl, aryl and heterocyclyl optionally substituted with one, two or three substituents selected from R<sup>Z</sup>;

R<sup>5</sup> is independently selected from:

- 1) H,
- 15 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) aryl, and
- 4) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,

said alkyl, cycloalkyl and aryl is optionally substituted with one or more substituents selected from R<sup>Z</sup>;

20

R<sup>6</sup> is NR<sup>7</sup>R<sup>8</sup>, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)perfluoroalkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, noboranyl, aryl, 2,2,2-trifluoroethyl, benzyl or heterocyclyl, said alkyl, cycloalkyl, noboranyl, aryl, heterocyclyl and benzyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>;

25

R<sup>7</sup> and R<sup>8</sup> are independently selected from:

- 1) H,
- 2) (C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,
- 3) (C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 30 4) (C=O)O<sub>b</sub>aryl,
- 5) (C=O)O<sub>b</sub>heterocyclyl,
- 6) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 7) aryl,
- 8) C<sub>2</sub>-C<sub>10</sub> alkenyl,



- 9) C<sub>2</sub>-C<sub>10</sub> alkynyl,  
 10) heterocyclyl,  
 11) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 12) SO<sub>2</sub>R<sup>a</sup>, and  
 5 13) (C=O)NR<sup>b</sup><sub>2</sub>,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R<sup>Z</sup>, or

R<sup>Z</sup> is selected from:

- 10 1) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>1</sub>-C<sub>10</sub>)alkyl,  
 2) O<sub>r</sub>(C<sub>1</sub>-C<sub>3</sub>)perfluoroalkyl,  
 3) (C<sub>0</sub>-C<sub>6</sub>)alkylene-S(O)<sub>m</sub>R<sup>a</sup>,  
 4) oxo,  
 5) OH,  
 15 6) halo,  
 7) CN,  
 8) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkenyl,  
 9) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>2</sub>-C<sub>10</sub>)alkynyl,  
 10) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>3</sub>-C<sub>6</sub>)cycloalkyl,  
 20 11) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-aryl,  
 12) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-heterocyclyl,  
 13) (C=O)<sub>r</sub>O<sub>s</sub>(C<sub>0</sub>-C<sub>6</sub>)alkylene-N(R<sup>b</sup>)<sub>2</sub>,  
 14) C(O)R<sup>a</sup>,  
 15) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>R<sup>a</sup>,  
 25 16) C(O)H,  
 17) (C<sub>0</sub>-C<sub>6</sub>)alkylene-CO<sub>2</sub>H,  
 18) C(O)N(R<sup>b</sup>)<sub>2</sub>,  
 19) S(O)<sub>m</sub>R<sup>a</sup>, and  
 20) S(O)<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>  
 30 21) NR<sup>c</sup>(C=O)O<sub>b</sub>R<sup>a</sup>,  
 22) O(C=O)O<sub>b</sub>C<sub>1</sub>-C<sub>10</sub> alkyl,  
 23) O(C=O)O<sub>b</sub>C<sub>3</sub>-C<sub>8</sub> cycloalkyl,  
 24) O(C=O)O<sub>b</sub>aryl, and  
 25) O(C=O)O<sub>b</sub>-heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from  $R^b$ , OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, halogen, CO<sub>2</sub>H, CN, O(C=O)C<sub>1</sub>-C<sub>6</sub> alkyl, oxo, and N( $R^b$ )<sub>2</sub>;

- 5  $R^a$  is (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, substituted or unsubstituted aryl, or heterocyclyl; and

$R^b$  is H, (C<sub>1</sub>-C<sub>6</sub>)alkyl, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, substituted or unsubstituted heterocyclyl, (C<sub>3</sub>-C<sub>6</sub>)cycloalkyl, (C=O)OC<sub>1</sub>-C<sub>6</sub> alkyl, (C=O)C<sub>1</sub>-C<sub>6</sub> alkyl or S(O)<sub>2</sub> $R^a$ ;

$R^c$  is selected from:

- 1) H,
- 2) C<sub>1</sub>-C<sub>10</sub> alkyl,
- 15 3) aryl,
- 4) C<sub>2</sub>-C<sub>10</sub> alkenyl,
- 5) C<sub>2</sub>-C<sub>10</sub> alkynyl,
- 6) heterocyclyl,
- 7) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- 20 8) C<sub>1</sub>-C<sub>6</sub> perfluoroalkyl,

said alkyl, cycloalkyl, aryl, heterocyclyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from  $R^Z$ , or

or a pharmaceutically acceptable salt or a stereoisomer thereof.
















25

4. The compound according to Claim 1 which is:

N-[4-(3-phenylquinoxalin-2-yl)benzyl]propane-1-sulfonamide.

30

5. The compound according to Claim 1 which is:



or a pharmaceutically acceptable salt or a stereoisomer thereof.

5        6.        A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

10       7.        A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 4.

15       8.        A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 5.

20       9.        A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1.

25       10.       A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 4.

30       11.       A method of inhibiting one or more of the isoforms of Akt in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 5.

35       12.       A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1.

40       13.       A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 4.

14. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 5.

5 15. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

10 16. A process for making a pharmaceutical composition comprising combining a compound of Claim 1 and a pharmaceutically acceptable carrier.

17. The composition of Claim 6 further comprising a second compound selected from:

- 15 1) an estrogen receptor modulator,  
2) an androgen receptor modulator,  
3) retinoid receptor modulator,  
4) a cytotoxic or cytostatic agent,  
5) an antiproliferative agent,  
20 6) a prenyl-protein transferase inhibitor,  
7) an HMG-CoA reductase inhibitor,  
8) angiogenesis inhibitor, and  
9) a PPAR- $\gamma$  agonist or PPAR- $\delta$  agonist.

25 18. The composition of Claim 17, wherein the second compound is an angiogenesis inhibitor selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP inhibitor, an integrin blocker, interferon- $\alpha$ , interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-  
30 O-(chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin and troponin-1.

19. The composition of Claim 18, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

20. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.

5 21. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 10 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 15 8) an angiogenesis inhibitor and
- 9) a PPAR- $\gamma$  agonist or PPAR- $\delta$  agonist.

22. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy and a compound selected from:

- 1) an estrogen receptor modulator,
- 2) an androgen receptor modulator,
- 3) retinoid receptor modulator,
- 4) a cytotoxic agent,
- 25 5) an antiproliferative agent,
- 6) a prenyl-protein transferase inhibitor,
- 7) an HMG-CoA reductase inhibitor,
- 8) an angiogenesis inhibitor and
- 30 9) a PPAR- $\gamma$  agonist or PPAR- $\delta$  agonist.

23. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.

TITLE OF THE INVENTION  
INHIBITORS OF AKT ACTIVITY

ABSTRACT OF THE DISCLOSURE

5           The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

10

60370846-040802

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**